SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions March listing by industry category 03/13

20130078183 - Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases: Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, the anti-CD20 antibody is veltuzumab and the anti-CD22 antibody is epratuzumab. Administration of the subject hexavalent DNL complexes induces apoptosis and cell death of target... Agent: Ibc Pharmaceuticals, Inc.

20130078182 - Structural variants of antibodies for improved therapeutic characteristics: Substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments are disclosed. They are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and... Agent: Immunomedics, Inc.

20130078184 - Fluorinated fructose derivatives for pet imaging: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.... Agent: The Governors Of The University Of Alberta

20130078185 - Nitroimidazole derivatives: The present invention provides novel compounds useful in the treatment and diagnosis of mycobacterial infections. Compounds of the present invention have enhanced biological properties as compared to the related known compounds. The present invention also provides a precursor compound useful in the synthesis of certain compounds of the invention, and... Agent: Ge Healthcare Limited

20130078186 - Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates: The present invention relates to compounds suitable as modulators of protein misfolding and/or protein aggregation. The compounds are particularly suitable as inhibitors of amyloid aggregate formation and/or modulators of amyloid surface properties, and/or as activators of degradation or reduction of amyloid aggregates.... Agent: Max-delbrueck-centrum Fuer Molekulare Medizin

20130078187 - Method for selecting bacteria with anti-oxidant action: The present invention relates to a method using Caenorhabditis elegans for screening of food grade bacteria which have a protective effect against oxidative stress.... Agent:

20130078189 - Formation and uses of europium complexes: The present invention provides a method of forming an oxidatively-stable aqueous Eu(II) complex by synthesizing ligands that coordinate to large, soft, electron rich metals like Eu(II). The invention also provides an oxidatively stable aqueous Eu(II) complex. The complex can be used for a variety of purposes some of which include,... Agent: Wayne State Univeristy

20130078188 - Activatable cell penetrating peptides with quenched fluorophores: The invention provides compositions useful as molecular probes. In particular, the invention provides activatable cell penetrating peptides comprising a fluorescence donor and a fluorescence acceptor. Exemplary fluorescence donors and fluorescence acceptors include compounds derived from cyanine. Also provided are ratiometric, multispectral, and excitation lifetime imaging methods for detecting the molecular... Agent: The Regents Of The University Of California

20130078190 - Anti-microbial hand towel with time-delay chromatic transfer indicator and absorbency rate delay: A disposable paper towel with an anti-microbial lotion and is provided with a chromatic transfer indicator which undergoes a delayed, visually perceptible color change at a predetermined time after the towel is wetted. An anti-microbial lotion on the towel increases water absorbency times (WAR) to further promote lotion transfer to... Agent: Georgia-pacific LLP

20130078191 - Aerosol composition: There is provided an aerosol composition which is high in fire safety and assures easy emulsification of an aqueous concentrate and a liquefied gas. The aerosol composition comprises 10 to 60 wt % of an aqueous concentrate and 40 to 90 wt % of a liquefied gas, and is obtained... Agent: Daizo Corporation

20130078193 - Sweetener compositions, methods of making same and consumables containing same: In one embodiment, the invention is to a sweetener composition comprising at least one sweetener and a pregelatinized starch, in particular to novel sweetener compositions that have a prolonged sweetener release rate and that provide a prolonged sweetening sensation to the consumer. The pregelatinized starch comprises particles having a plurality... Agent: Nutrinova Nutrition Specialties & Food Ingredients Gmbh

20130078192 - Use of neoflavonoids for flavor modification: The present invention relates primarily to the use of one or a plurality of neoflavonoids of formula (I) and/or one or a plurality of physiologically acceptable salts of one or a plurality of neoflavonoids of formula (I) for flavor modification, in particular for altering or masking a bitter, astringent and/or... Agent: Symrise Ag

20130078194 - Compositions for dental treatment comprising lipoteichoic acids or parts thereof like mono- or polyglycerphosphates: The present invention refers to compositions for the treatment or prophylaxis of infectious or inflammatory processes in the oral cavity (cavitas oris) including dental hygiene, the composition comprising lipoteichoic acids and glycerophosphate derivatives, preferably added into a dental hygiene product like toothpastes, toothgels, creams or rinsing fluids, the use of... Agent: Lunamed Ag

20130078195 - Adhesive dental bleaching compositions containing polyvinylpyrrolidone: A dental bleaching composition comprises a dental bleaching agent and a polyvinylpyrrolidone thickening agent. The bleaching composition may include water, flavoring agents, a basic substance and desensitizing agents, as desired. Polyvinylpyrrolidone avoids acid etching and chelation of teeth that were problematic in bleaches using carbomer as a thickener. A delivery... Agent: Ultradent Products, Inc.

20130078196 - Dental sterilizing water, method for producing the water, and device for producing the water: This aims to produce dental sterilizing water having not only a sterilizing action but also an action to break a bio-film. Provided is a sterilizing water producing device (51) comprising a stock solution tank (3) for storing a stock solution (52), a stroke pump (4) connected in communication to the... Agent: Perfect Perio Co., Ltd.

20130078197 - Therapeutic oral composition: Disclosed are therapeutic oral compositions useful in the treatment of a variety of oral disorders, in which the composition can provide blockage of dentinal tubes, while at the same time provide antibacterial and anti-caries efficacy. The compositions include arginine in free or salt form, a mucoadhesive polymer, and at least... Agent: Colgate-palmolive Company

20130078198 - Novel use: This invention relates to the use of sodium dodecylbenzene sulphonate (SDDBS) for helping to prevent or remove surface deposited stains from natural teeth and dental prostheses and oral care compositions comprising SDDBS for such use.... Agent: Glaxo Group Limited

20130078203 - Carotenoid sunscreen: The invention concerns methods of treating or preventing the effects of irradiation in a human or non-human animal using sarcinaxanthin and related compounds (particularly its glycosides) as well as photoprotective compositions and their use to prepare photoprotective or photoprotected products.... Agent: Promar As

20130078202 - Inhibition of the formation of ages: The present invention relates to the use of an active substance that promotes the inhibition of the formation of AGEs, for preparing a composition to prevent and/or combat the reduction in elastic and plastic properties of tissues, and in particular of the skin, for inhibiting the formation of AGEs, or... Agent: Basf Beauty Care Solutions France S.a.s.

20130078199 - Topical sunscreen compositions: Substantially anhydrous compositions including at least 10% by weight of a C2 or C3 mono-alcohol, about 1.5% or less by weight of an organic UV-filter; and an oil portion including one or more oils, the oil portion having an interfacial tension with water of greater than 9 and less than... Agent:

20130078200 - Topical sunscreen compositions: Substantially anhydrous compositions including at least 10% by weight of a C2 or C3 mono-alcohol, a solid, organic UV-filter other than oxybenzone dissolved therein; and an oil portion including one or more oils, the oil portion having an interfacial tension with water of greater than 9 and less than 45,... Agent:

20130078201 - Topical sunscreen compositions: Substantially anhydrous compositions including at least 10% by weight of a C2 or C3 mono-alcohol, a solid, organic UV-filter dissolved therein; and an oil portion including one or more oils, the oil portion having an interfacial tension with water of greater than 9 and less than 13.9. The composition has... Agent:

20130078205 - Compound, composition, and method for protecting skin from high energy visible light: A compound, composition, and method for the protection of skin from the harmful effects of radiation, and particularly the harmful effects of high energy visible (HEV) radiation, are disclosed. The compound is a melanin derivative that can be formulated into compositions containing the melanin derivative and a suitable carrier. The... Agent: Lipo Chemicals Inc.

20130078204 - Topical sunscreen compositions: Substantially anhydrous compositions including at least 10% by weight of a C2 or C3 mono-alcohol, a solid, organic UV-filter dissolved therein; and an oil portion including one or more oils, the oil portion having an interfacial tension with water of greater than 9 and less than 32.5, where the composition... Agent:

20130078207 - Artificial nail composition, nail covering agent, and method for forming cover film: A novel artificial nail composition (gel nail composition) is provided. The artificial nail composition is curable with ultraviolet rays to form an artificial nail, and includes an ultraviolet-curable resin and pearl powder dispersed in the ultraviolet-curable resin.... Agent: Matsukaze Co., Ltd.

20130078206 - Capsule of salts for pedicure bath: A water-soluble capsule for use in a pedicure bath that comprises the following substances: Dead Sea salts, olive oil, sodium bicarbonate, citric salt, starch, and fragrance. A method of manufacturing the capsule that includes the following stages: The aforementioned substances are placed in a mixer and a little water is... Agent:

20130078208 - Quaternary dialkanolamine esters: The invention relates to novel quaternary ammonium compounds of the esterquat type, to a method for the production thereof, and to the use thereof in formulations.... Agent: Evonik Goldschmidt Gmbh

20130078209 - Compositions and methods for treating conditions of compromised skin barrier function: Compositions and methods of treating conditions of compromised skin barrier function are described.... Agent:

20130078210 - Chitosan derivatives for inactivation of endotoxins and surface protection of nanoparticles: The present disclosure provides a polymer comprising a derivative of chitosan, wherein the derivative is zwitterionic, as well as methods of using the polymer. In addition, the present disclosure provides a nanoparticle structure comprising a derivative of chitosan and a dendrimer, as well as methods of utilizing the nanoparticle structure.... Agent: Purdue Research Foundation

20130078212 - Double stranded rna constructs to control ants: Disclosed are double stranded RNA constructs used to inhibit the expression of guanine nucleotide binding (3-subunit to induce mortality in ants classified in the Formicidae family.... Agent:

20130078211 - Murgantiol as a stink bug synergistic attractant for use outdoors: Provided herein are uses of the Harlequin bug pheromone, murgantiol, alone or in a synergistic combination with at least one other stink bug attractant, such as methyl (2E,4E,6Z)-decatrienoate or methyl (2E,4Z)-decadienoate, or both, for attracting stink bugs such as the brown marmorated stink bug in outdoor settings. Stink bug traps... Agent: Sterling International Inc.

20130078214 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Bristol-myers Squibb Company

20130078213 - Thrombopoietin mimetics: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected... Agent: Glaxosmithkline LLC

20130078215 - Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions: Described herein are methods for treating a subject suffering from an inflammatory, autoimmune, or heteroimmune condition by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a compound that is a selective inhibitor of histone deacetylase 8. Also described herein are methods for decreasing secretion of... Agent: Pharmacyclics, Inc.

20130078216 - Liver targeting molecules: The present invention relates to molecules that can be targeted to the liver. These liver targeting molecules (e.g.fusions and conjugates) comprise proteins, antibodies or antibody fragments such as immunoglobulin (antibody) single variable domains (dAbs) and also one or more additional molecules which it is desired to deliver to the liver... Agent:

20130078217 - 2'-chloroacetylenyl substituted nucleoside derivatives: As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related β-D and β-L-nucleoside... Agent:

20130078218 - Hepatitis c therapies: The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections.... Agent:

20130078219 - Genetically modified paramyxovirus for treatment of tumor diseases: The present invention relates to a genetically modified Paramyxovirus, a pharmaceutical composition comprising this paramyxovirus, the use of a genetically modified Paramyxovirus for the therapeutic and/or prophylactic treatment of a tumor disease, and a method for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of a... Agent: Eberhard-karls-universitaet Tuebingen Universitaetsklinikum

20130078224 - Induction/monitoring of arteriogenesis using sdf1 and pdgfb or inhibition of phd2: The disclosure relates to the field of ischemia and how to increase tissue perfusion in ischemic tissue by cellular therapy. Specifically, the beneficial effects of myeloid (bone marrow-derived) cells with a particular arteriogenic gene expression profile are shown, and it is shown that increased arteriogenesis and perfusion is specifically due... Agent: Vib Vzw

20130078225 - Method for modulating microrna content in living beings and the use thereof: The present invention relates to a method for modulating miRNA content in living beings and the use thereof, whereof the miRNAs are delivered initiatively and selectively by microparticles/MVs/exosomes to the circulatory system and target cells/tissues to perform various functions. The invention provides a novel combination of molecules that mediates the... Agent: Jiangsu Mingma Biotech Co., Ltd.

20130078220 - Dopaminergic neuronal survival-promoting factors and uses thereof: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for... Agent:

20130078222 - Intervertebral disc nucleus pulposus stem cell/progenitor cell, the cultivation method and intended use thereof: Provided are intervertebral disk nucleus pulposus stem cells or progenitor cells that may be used for treatment of intervertebral disk disorders. An intervertebral disk nucleus pulposus cell is characterized by being isolated from the intervertebral disk nucleus pulposus of a vertebrate and is positive for at least one surface marker... Agent: Tokai University Educational System

20130078223 - Method and composition for inducing human pluripotent stem cells: The present invention provides pluripotent stem cell like (PSCL) cells or clones, a culture medium therefore, and a supernatant thereof, and methods of making and using the same.... Agent: The Regents Of The University Of California

20130078221 - Multipotent adult stem cell derived from canine umbilical cord blood, placenta and canine fetus heart, method for preparing the same and cellular therapeutics containing the same: The present invention relates to multipotent adult stem cells derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart, and a method for preparing the same as well as a cellular therapeutic agent containing the same, more specifically, to a multipotent adult stem cell isolated... Agent: Seoul National University Industry Foundation

20130078226 - Method for reconstructing immune function using pluripotent stem cells: According to the present invention, there are provided a method for producing a human T cell, which comprises the steps of inducing an iPS cell from a human T cell, and differentiating the iPS cell into a T cell; a pharmaceutical composition comprising the T cell produced by the method;... Agent: The University Of Tokyo

20130078227 - Embedded chimeric peptide nucleic acids and uses thereof: and uses thereof, wherein X is A or C and Y is A or C with the proviso that when X is A, Y is C, and when X is C, Y is A; A represents an oligopeptide structure, the sequence of which comprises a sequence which renders the compound... Agent:

20130078228 - Vitamin-containing nutrition infusion for administration through peripheral vein: A nutrition infusion is provided for administration through a peripheral vein that contains a vitamin B group and vitamin C stably and includes two solutions of a sugar solution and an amino acid solution. In the nutrition infusion for administration through a peripheral vein, the sugar solution contains vitamin B1,... Agent: Ajinomoto Co., Inc.

20130078230 - Dose escalation enzyme replacement therapy for treating acid sphinogmyelinase deficiency: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.... Agent: Mount Sinai School Of Medicine Of New York University

20130078231 - Dose escalation enzyme replacement therapy for treating acid sphinogmyelinase deficiency: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.... Agent: Mount Sinai School Of Medicine Of New York University

20130078229 - Methods and compositions for the treatment of cancer: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.... Agent:

20130078232 - Compositions and methods useful for stabilizing protein-containing formulations: The invention relates to use of non-surfactant compounds including, for example, polyoxyethylene (POE) sorbitans and polyethylene glycols (PEGs), for stabilizing protein-containing formulations and for the prevention of aggregation of proteins in such formulations.... Agent: Genentech, Inc.

20130078233 - Compositions and methods using same for treating amyloid-associated diseases: Compounds having one or more phenol moieties, derivatives thereof, compositions containing same and uses thereof for the treatment of amyloid-associated diseases are provided.... Agent: Tel Aviv University Future Technology Development L.p.

20130078234 - Anti b7-h3 antibody: An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding... Agent: Daiichi Sankyo Company, Limited

20130078240 - 4-1bb binding molecules: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of... Agent: Pfizer Inc

20130078236 - Anti-cd28 humanized antibodies: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through... Agent:

20130078241 - Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in... Agent: Immunogen, Inc.

20130078242 - Antibodies with immune effector activity and that internalize in endosialin-positive cells: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic... Agent: Morphotek, Inc.

20130078237 - Cd27l antigen binding proteins: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.... Agent:

20130078239 - Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member... Agent: Millennium Pharmaceuticals, Inc.

20130078238 - Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy: A method or composition comprising an anti-CD3 immune molecule for treatment of hepatitis in a subject.... Agent: Nasvax Ltd.

20130078235 - Neuregulin based compositions and uses thereof for preventing, treating or delaying the myocardial ischemia-reperfusion injury: The present invention elates to the applications of neuregulin in the preparation of drugs for preventing, treating or delaying the ischemia-reperfusion injury (IRI) in mammals, particularly in humans. In particular, the present invention provides the neuregulin based compositions and methods for preventing, treating or delaying the myocardial ischemia-reperfusion injury. Specifically,... Agent: Zensun (shanghai) Science & Technology Limited

20130078245 - Antibodies to the c3d fragment of complement component 3: The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they... Agent: The Regents Of The University Of Colorado, A Body Corporate

20130078243 - Conjugate molecule: This invention relates to a therapeutic molecule capable of suppressing an immune response against an organ or tissue transplantation in a patient. In particular, the invention relates to a conjugate comprising a first portion connected to a second portion, wherein the first portion binds to an MHC Class I molecule... Agent: King's College Hospital Nhs Foundation Trust

20130078244 - Methods for detecting and regulating alopecia areata and gene cohorts thereof: The invention provides for methods for controlling hair growth by administering a HLDGC modulating compound to a subject. The invention further provides for a method for screening compounds that bind to and modulate polypeptides encoded by HLDGC genes. The invention also provides methods of detecting the presence of or a... Agent:

20130078246 - Biomarkers and methods for detecting and treating spinal and joint pain: Biomarkers, including isolated fibronectin-aggrecan complexes that correlate with spinal or joint pain and inflammation, and methods for their detection are provided. Also provided are methods for identifying treatment sites in the spine or joint for treatment of pain and inflammation by detecting the presence of, or increased levels of, fibronectin-aggrecan... Agent:

20130078247 - Bispecific binding molecules binding to dii4 and ang2: Bispecific binding molecules binding to both DII4 and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with DII4- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic... Agent: Boehringer Ingelheim International Gmbh

20130078248 - Bispecific binding molecules binding to vegf and ang2: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic... Agent: Boehringer Ingelheim International Gmbh

20130078249 - Bispecific t cell activating antigen binding molecules: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for... Agent:

20130078250 - Bispecific t cell activating antigen binding molecules: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for... Agent:

20130078251 - Anti-mcsp antibodies: The invention provides anti-MCSP antibodies and methods of using the same.... Agent:

20130078252 - Combination treatments comprising c-met antagonists and b-raf antagonists: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.... Agent: Genentech, Inc.

20130078253 - Cancer targets and uses thereof: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating... Agent: Celera Corporation

20130078254 - Genes of an otitis media isolate of nontypeable haemophilus influenzae: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.... Agent: Nationwide Children's Hospital, Inc.

20130078255 - Serum and tissue biomarkers of human hcc: The application is based on the surprising finding that proteins regulated by increased c-myc activity in the liver can be used as sis and/or treatment monitoring of cancer and dysplasia, in particular of liver cell dysplasia and hepatocellular carcinoma (HCC), and wherein the proteins are selected from a first group... Agent:

20130078256 - Novel hiv reverse transcriptase inhibitors: e

20130078257 - Use of an active substance binding to cd28 for producing a pharmaceutical composition for the treatment of b-cll: The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the... Agent: Theramab Gmbh

20130078258 - Cachexia treatment: Administration of an antibody that specifically binds IL-1α is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.... Agent: Xbiotech, Inc.

20130078260 - Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media: The present invention provides a compound which targets the VEGF and/or HIF pathways for use in the treatment and/or prevention of otitis media in a subject. The invention also provides a pharmaceutical composition comprising such a compound and a method for treating and/or preventing otitis media in a subject which... Agent: Medical Research Council

20130078259 - Method of diagnosing and preventing pneumococcal diseases using pneumococcal neuraminidases: A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of S. pneumoniae strains CGSP14, wherein administration of the recombinant pneumococcal neuraminidases elicits an... Agent: Chang Gung Medical Foundation, Linkou Branch

20130078261 - Enveloped virus vaccine and method for production: The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen.... Agent: Baxter Healthcare S.a.

20130078263 - Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants: Disclosed herein are methods and compositions comprising anti-HLA-DR antibodies for treatment of allogeneic and xenogeneic immune responses occurring in organ transplant rejection and other immune dysfunction diseases. In preferred embodiments, the anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions... Agent: Immunomedics, Inc.

20130078262 - Fc receptor binding proteins: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.... Agent: Dyax Corp.

20130078264 - Removal of serine proteases by treatment with finely divided silicon dioxide: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized... Agent: Baxter International Inc.

20130078265 - Laser-based vaccine adjuvants: The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine... Agent: Ooo "npt Mbp Gormezis"

20130078269 - Amyloid beta peptides, assemblies thereof, and related methods: The present invention provides amyloid β peptide assemblies composed of at least three amyloid β peptide subunits, wherein at least one of the amyloid β peptide subunits is an amyloid β peptide analog. The invention further relates to metal complexes of amyloid β peptide assemblies and the use of amyloid... Agent: Northwestern University

20130078267 - Epitopes related to coeliac disease: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.... Agent:

20130078270 - Her-2 peptides and vaccines: The present invention provides (a) isolated immunogenic HER-2 peptides capable of inducing immune responses against human HER-2 receptor; (b) isolated nucleic acid molecules encoding an isolated immunogenic HER-2 peptide; (c) plasmid constructs comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; (d) vaccine compositions comprising an isolated immunogenic... Agent: Pfizer Inc.

20130078266 - Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction): The invention provides methods for inhibiting T-cell mediated rejection of a xenotransplanted organ by blocking the delivery of co-stimulatory signal 2 (the B7/CD28 interaction) prevent the activation of xenoreactive T-cells in the recipient. In a first aspect, co-stimulation is prevented by administration to the organ recipient of a soluble form... Agent:

20130078268 - Vaccine compositions and methods of use thereof: The present invention relates to vaccine composition and methods for eliciting a protective immune response in animals against an endogenous peptide of the formula pGlu-Pro-Pro-Gly-Gly-Ser-Lys-Val-Ile-Leu-Phe, the composition comprising an immunizing effective amount of said peptide or conjugates thereof. Further, the invention relates to methods of treating cancer, cardiovascular diseases, and... Agent:

20130078271 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection.... Agent: Sanofi Pasteur Limited/sanofi Pasteur Limitee

20130078272 - Fungicidal compounds and methods of their use: Antifungal compounds, an antifungal compound extracted from Epicoccum purpurascens, also known as Epicoccum nigrum, methods of producing the antifungal compounds, isolates and compositions comprising the antifungal compounds, and methods of using the antifungal compounds.... Agent: Auckland Uniservices Limited

20130078273 - Vault compositions for immunization: Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.... Agent:

20130078274 - Live, oral vaccine for protection against shigella dysenteriae serotype 1: The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof;... Agent: Government Of The United States Of America, As Represented By The Secretary

20130078275 - Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells: Embodiments described herein provide novel bacterial-based methods, systems, and delivery vehicles capable of delivering DNA, RNA, proteins, and other cargo into targeted mammalian cells, both in vitro and in vivo, with high efficiency. Delivery vehicles may be used to deliver molecules such as prophylactic or therapeutic proteins, DNA, shRNA, DNA... Agent: The Board Of Trustees Of The University Of Illinois

20130078276 - Vectors expressing hiv antigens and gm-csf and related methods of generating an immune response: The disclosure provides vectors encoding one or more HIV antigens and GM-CSF. Also provided are methods of inducing an immune response in a subject, methods of treating a subject having HIV, and methods of manufacturing a medicament for inducing an immune response that require the use of these vectors and... Agent:

20130078277 - Infectious hepatitis c virus-high producing hcv variants and use thereof: An objective of this invention is to provide an HCV strain with a high capacity for virus production in a cell culture system. This invention provides a nucleic acid encoding a polyprotein precursor of the hepatitis C virus JFH1 strain having one or more amino acid substitutions, wherein the polyprotein... Agent: Institute Of Microbiology, Chinese Academy Of Sciences

20130078278 - Vaccine for protection against shigella sonnei disease: Compositions and methods for protecting a susceptable host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.... Agent: Government Of The United States Of America, As Represented By The Secretary

20130078279 - Furin-knockdown and gm-csf-augmented (fang) cancer vaccine: Compositions and methods for cancer treatment are discloses herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs to knock down the expression of furin... Agent: Gradalis, Inc.

20130078280 - Cyclosporine analogue mixtures and their use as immunomodulating agents: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis... Agent:

20130078281 - Activators of innate immunity: The present invention includes IFNS activating agents that activate expression of IFN-β, activate NF-κB expression, activate an innate immune response, activate the expression of one or more cytokines, and/or induce the expression of interferon beta (IFN-β) through a RNase L and/or MDA5-dependent pathway. Such IFNS activating agents include single stranded... Agent: University Of Georgia Research Foundation, Inc.

20130078291 - Bio-adhesive agent comprising surface-modified hydroxyapatite and use thereof: The present invention relates to a bio-adhesive agent comprising a surface-modified hydroxyapatite and its use. More specifically, the present invention relates to a bio-adhesive agent for the adhesion between bone and bone, bone and tissue, bone and cartilage, or bone and tendon, or for the adhesion of a shield between... Agent: University-industry Cooperation Group Of Kyunghee University

20130078286 - Drug delivery system: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a... Agent: Msd Oss B.v.

20130078282 - Formulations decreasing particle exhalation: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary... Agent: Pulmatrix, Inc.

20130078290 - Gastroretentive dosage forms of gaba analogs: The present invention relates to gastroretentive dosage forms of gamma aminobutyric acid (“GABA”) analogs, and to processes for preparation of the same. The present invention provides gastroretentive dosage forms comprising GABA analog, at least one swelling agent and at least one non-swelling release retardant.... Agent: Rubicon Research Private Limited

20130078285 - Implant for tissue repair: Mono- and multi-layered implants include at least one porous layer made from a freeze dried aqueous solution containing chitosan, the solution having a pH of less than about 5.... Agent: Sofradim Production

20130078289 - Indigestible polymer: starch acetate -based film coatings for colon targeting: A colon targeted delivery dosage form for controlled release of an active ingredient, includes an active ingredient coated in a polymeric mixture of: a water insoluble polymer composition containing at least a starch acetate, and an indigestible polysaccharide composition. The use and method for making the same are also described.... Agent: Roquette Freres

20130078288 - Method of treating cancer: A method and composition for administering a therapeutic composition to a lesion comprising about 20% to about 50% ethanol and other novel therapeutic agents.... Agent:

20130078283 - Novel amphiphiles: Disclosed herein is a compound of structure (A): In this compound, X is either O or S, R1 is a rigid group, R2 is a hydrophilic group such that (A) is capable of self-assembly in water, and R3 is an organic group.... Agent:

20130078287 - Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist: Pharmaceutical compositions of a H2 receptor antagonist and ibuprofen are provided herein. The compositions comprise, e.g., a core and a shell separated by a barrier layer, bilayered or trilayered compositions, or liquid formulations. Also provided are methods of making the pharmaceutical compositions, and methods of treatment comprising administering the pharmaceutical... Agent: Horizon Pharma Usa, Inc.

20130078284 - Pharmaceutical formulations: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.... Agent:

20130078292 - Composition for preventing or treating dentin-associated symptoms or diseases, and method using the same: Provided is a formulation for oral teeth, which includes a plurality of calcium ion carriers and a plurality of calcium-containing particulates. The particulates are carried by the calcium ion carriers, such that the formulation can prevent or rapidly treat dentin-associated symptoms or diseases, while providing a prolonged prophylactic or therapeutic... Agent: Sancastle Worldwide Corporation

20130078293 - Hybrid powder of halloysite nanotube and light-scattering nanoparticle, method for preparing the same, and uvscreening cosmetic composition containing the same as active ingredient: The present invention provides a hybrid powder of halloysite nanotubes and light-scattering nanoparticles, a method for preparing the same, and a UV-screening cosmetic composition containing the same as an active ingredient. The hybrid powder of halloysite nanotubes and light-scattering nanoparticles according to the present invention, in which the light-scattering nanoparticles... Agent:

20130078294 - Multi-active microtargeted anti-aging skin care cream polymer technology: A comprehensive, single agent cosmetic cream or lotion containing a high number of ingredients that target anti-aging in a defined manner. The cream or lotion contains a high number and variety of active substances that demonstrate excellent safety and efficacy in all of the various defined categories of skin aging,... Agent: Ny Derm LLC

20130078295 - Skin antiaging treatment: A method for skin antiaging treatment including administering Botulinum toxin to an area of facial and/or neck skin, combined with the administration of a cosmetic or pharmaceutical composition having a cosmetically or pharmaceutically effective amount of at least one peptide derived from the SNAP-25 protein and/or at least one enkephalin-derived... Agent: Lipotec S.a.

20130078297 - Aqueous active ingredient composition: m

20130078296 - Composition and method of time releasing essential oils for animal repellency and pesticide use: The invention is a method of releasing essential oils over at least 30 days which includes encapsulating one or more essential oils in one or more carbohydrate and one or more protein. Additional embodiments include pesticides and/or additional repellents.... Agent: Liquid Holding Company, Inc.

20130078298 - Gaseous nitric oxide-sequestering products and processes of preparing same: A process of preparing articles having gaseous NO sequestered therein is disclosed, as well as articles prepared thereby. Also disclosed are articles having gaseous NO sequestered therewithin and having reduced amount of oxygen-containing and/or nitrogen-containing reactive species. Also disclosed are processes of preparing packaged articles having a non-gas permeable package... Agent: Enox Biopharma, Inc

20130078299 - Transdermal patches having ionized beam crosslinked polymers and improved release characteristics: Crosslinked hydrogel-based transdermal pharmaceutical formulations. The hydrogel transdermal formulations. Transdermal patches are useful for administering a variety of drugs to patients. The transdermal patches here employ crosslinked-hydrogels generated through irradiation, thus eliminating any residual effects associated with chemical- or UV-based crosslinking procedures. The transdermal patches may be formed from a... Agent: Alliqua, Inc.

20130078300 - Bioabsorbable polymers from bioabsorbable polyisocyanates and uses thereof: Novel bioabsorbable and/or biocompatible polyurethanes, polyureas, polyamideurethanes and polyureaurethanes with tunable physical, mechanical properties and hydrolytic degradation profiles are provided for use in biomedical applications such as stents, stent coatings, scaffolds, foams, and films. The disclosed polymers may be derived from biocompatible and/or bioabsorbable polyisocyanates. The present invention also relates... Agent: Bezwada Biomedical, LLC

20130078301 - Methods for stimulating growth and preventing loss of human hair: A method for preventing the loss of human hair includes providing a topical composition including a purified oil extract from Melaleuca alternifolia, also known as tea tree. The method may further include applying the topical composition to the skin surrounding the follicles of the human hair at least once a... Agent: Nnc Blending LLC

20130078302 - Protein c zymogen and methods of use thereof to prevent cancer metastases: Compositions and methods useful for the inhibition of cancer metastasis are disclosed.... Agent: The Children's Hospital Of Philadelphia

20130078303 - Soft-gelatin capsule formulation: The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin... Agent: Sucampo Ag

20130078304 - Controlled release formulation for treating sleep disorders: The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form and Zolpidem or a pharmaceutically acceptable salt thereof in sustained release form, wherein Zaleplon or a pharmaceutically acceptable salt thereof and Zolpidem or a pharmaceutically... Agent: Taiwan Biotech Co., Ltd.

20130078305 - Pharmaceutical compositions for the coordinated delivery of nsaids: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe... Agent: Pozen, Inc.

20130078306 - Medicaments containing vardenafil hydrochloride trihydrate: The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method... Agent: Bayer Intellectual Property Gmbh

20130078307 - Nicotine-containing pharmaceutical composition: A composition intended to be employed for therapeutic purposes incorporates a nicotinic compound, a sugar substitute, and a sugar alcohol syrup. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The composition is... Agent: Niconovum Usa, Inc.

20130078308 - Encapsulation device, medical capsules, and encapsulation method: An encapsulation device includes: a fluid injection device that injects a first liquid forming a core; a liquid film holder that holds in film form a second liquid forming a shell containing the core; and a liquid contact device that makes the shell in contact with a third liquid, in... Agent: Seiko Epson Corporation

20130078309 - Oral particulate antitumor preparation: An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. An oral particulate antitumor preparation, in which a particulate composition... Agent: Taiho Pharmaceutical Co., Ltd.

20130078310 - Multi-block copolymers for the preparation of stabilized micelles: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.... Agent: Intezyne, Inc.

20130078312 - Biodegradable putty compositions and implant devices, methods, and kits relating to the same: Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include... Agent:

20130078311 - Composition for treating and/or preventing osteoporosis: The invention relates to a composition comprising deer velvet antler blood (DVAB) in combination with velvet antler for use in the treatment and/or prevention of osteoporosis and a method for treating and/or preventing osteoporosis, comprising administering a therapeutically effective amount of a composition comprising DVAB and velvet antler to a... Agent:

20130078313 - Milk derived composition and use to enhance muscle mass or muscle strength: The invention relates to the production of compositions containing milk products for use as a nutritional supplement. More specifically, it relates to compositions containing whey growth factor extract, as well as methods for supplementing the nutritional needs of individuals undertaking resistance exercise training. According to one aspect of the invention,... Agent: Murray Goulburn Co-operative Co Limited

20130078314 - Transdermal method of delivering nutrients into human body: The present invention is about a transdermal method that deliveries nutrients from fresh animal organs to the systemic circulation of the human body by applying the juice or chopped pieces of the fresh animal organs on the skin of the human body and allowing the nutrients to absorb through the... Agent:

20130078315 - Eggshell antimicrobial agent and method of use: Provided herein is a composition and a method for inhibiting bacterial growth.... Agent: Biosynergy, Inc.

20130078316 - Methods and compositions for irrigation of mucosal tissues: A synthetic endotracheal irrigant for preventing, treating, and reducing infections, including mucosal infections in patients, including infants. A method for producing a formulation of the synthetic endotracheal irrigant with a water content of about 98% (w/w) to about 99.9(w/w) and a total mineral content of less than about 5.0% (w/w),... Agent:

20130078317 - Zinc-containing compositions for the treatment of diseases, illnesses and syndromes associated with exposure to pore forming toxins: Embodiments of the invention relate to compositions and methods of using the same to treat conditions caused by exposure to a pore-forming toxin.... Agent:

20130078318 - Combination dosage forms and therapies for supporting bone health: Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.... Agent: Primus Pharmaceuticals Inc.

20130078319 - Detection of ovarian cancer: Among other things, the present disclosure provides a method including the steps of: obtaining a uterine sample; and detecting and/or characterizing in the uterine sample an ovarian cancer biomarker (e.g., CA125).... Agent: Memorial Sloan-kettering Cancer Center

20130078320 - Composition for treating hearing loss: A composition to be administered to a mammal for treating hearing loss is disclosed herein. The composition consists essentially of a biologically effective amount of vitamin A, vitamin C, vitamin E, and a vasodilator comprising magnesium. The composition optionally includes a withanolide and/or resveratrol. The vitamin A, vitamin C, vitamin... Agent: The Regents Of The University Of Michigan

20130078321 - Methods for treating patients who are candidates for inhaled nitric oxide treatment: Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in the patient, leading to pulmonary edema.... Agent: Ino Therapeutics LLC

20130078322 - Therapeutic composition produced using camellia sinensis leaves and hydrogen peroxide: Methods of and compositions for producing and using plant-based materials are provided. The methods include using biopolymers or their synthetic equivalents combined with a stable source of reactive oxygen species that when applied to or combined with a separate source of oxido-reducing enzyme or catalyst will cause the formation of... Agent: Liveleaf, Inc.

20130078323 - Adaptogenic activity of labisia pumila extract: The present invention provides a process of extracting the leaves of Labisia pumila with water into a free flowing powder using accelerated solvent system and drying. The invention also relates to the immunopotentiating effects of the extract against stress. The extract has effects on fatigue, hypoxia time, potentiation of swimming... Agent: Holista Biotech Sdn. Bhd.

20130071319 - Compositions and methods for surface abrasion with frozen particles: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least... Agent: Searete LLC

20130071320 - Immunotherapy of autoimmune disorders using antibodies which target b-cells: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.... Agent: Immunomedics, Inc.

20130071321 - Delivery of agents to inflamed tissues using folate-targeted liposomes: The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease,... Agent: Purdue Research Foundation

20130071322 - Medical treatment applications of swellable and deformable microspheres: A method for medical treatment was developed in which microspheres with novel properties are administered in a mammal. The microspheres are made using a novel process that results in microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres... Agent: E I Du Pont De Nemours And Company

20130071325 - Monoclonal antibodies for treatment of cancer: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma,... Agent:

20130071324 - Radioactive metal-labeled anti-cadherin antibody: An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by... Agent: Fujifilm Ri Pharma Co., Ltd.

20130071323 - Therapies for hematologic malignancies:

20130071326 - Universal cell-directed theranostics: The present invention provides modified stem cells that comprise a delivery system that comprises at least one microparticle or nanoparticle, wherein the at least one microparticle or nanoparticle comprises an active agent. The present invention also provides delivery methods that comprise the administration of the modified stem cells to a... Agent: Board Of Regents Of The University Of Texas System

20130071327 - Homoglutamic acid derivatives: This invention relates to homoglutamic acid derivatives suitable for labeling or already labeled with 18F or 19F, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging.... Agent: Piramal Imaging Sa

20130071328 - Propynoic acid carbamoyl methyl-amides and pharmaceutical compositions and methods based thereon: This invention discloses a series of novel propynoic acid carbamoyl methyl-amides (PACMAs), methods for synthesizing the PACMAs and pharmaceutical compositions containing the PACMAs. These novel compounds and compositions show cytotoxicity in cancer cells and are useful as lead compounds for anti-cancer drugs or pharmaceutical agents. This invention also discloses treatment... Agent: University Of Southern California

20130071329 - Theranostic delivery systems with modified surfaces: The present invention pertains to therapeutic compositions and delivery systems comprising at least one microparticle or nanoparticle. In various embodiments, the surface of the microparticle or nanoparticle is modified or functionalized with at least a portion of an isolated cellular membrane, such as an isolated plasma membrane. In addition, the... Agent: Board Of Regents Of The University Of Texas System

20130071330 - Methods of identifying agents effective to treat cognitive decline and diseases associated therewith: Embodiments described herein are directed to methods of identifying agents effective to treat cognitive decline and diseases associated therewith. Embodiments described herein are also directed to kits for performing methods described herein. Embodiments described are also directed to methods of diagnosis and uses of the same.... Agent:

20130071331 - Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof: A method for purifying a non-spreading botulinum toxin that causes local muscle paralysis and a non-spreading botulinum toxin obtained thereby includes the steps of: subjecting a purified botulinum toxin type A product to ion-exchange chromatography using a controlled pH of buffer, concentration of sodium chloride (NaCl), thereby separating the botulinum... Agent: Medexgen Incorporated

20130071332 - Labeled molecular imaging agents and methods of use: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.... Agent: General Electric Company

20130071334 - Method and system for identifying, assessing, and managing cancer disease: Techniques described herein generally relate to identifying, assessing, and managing cancer diseases. Some example methods may include constructing one or more quantitative metrics for the cancer disease in a selected population of other patients retrieved during the scheduling interval, acquiring a first set of numeric biomarker data for the patient... Agent: Varian Medical Systems, Inc.

20130071333 - Method and system for identifying, assessing, and managing cancer growth rates and potential metastasis: Techniques described herein generally relate to identifying, assessing, and managing cancer growth rates and potential metastasis. Some example methods may include constructing one or more quantitative metrics for the potential metastasis in a selected population of other patients, acquiring a first set of numeric biomarker data for the patient before... Agent: Varian Medical Systems, Inc.

20130071335 - X-ray contrast media compositions and methods of using the same: Embodiments disclosed herein relate to improved X-ray contrast media compositions and methods of using the same for treating symptoms related to allergic reactions, inflammatory conditions, symptoms of the common cold and certain cancers.... Agent:

20130071336 - Injectable cross-linked polymeric preparations and uses thereof: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic... Agent: Ben-gurion University Of The Negev

20130071337 - Interomone compositions and their use to modify behavior in different vertebrate species: A composition comprising an interomone is described for the modification of undesirable or harmful stress-related behaviors or other behaviors or physiology in a variety of vertebrate species, as well as methods of using the compositions in vertebrates from a species different than the species in which the interomone is a... Agent: Sergeant's Pet Care Products, Inc.

20130071338 - Formulation comprising nicotine and a cation exchange resin: A method of producing a nicotine delivery product includes a mixture having nicotine, a cation exchange resin and water. The water content of the mixture is between 5 and 75 wt. % relative to the whole mixture. The mixture is combined with further components of the nicotine delivery product.... Agent: Fertin Pharma A/s

20130071339 - High-purity steviol glycosides: Methods of preparing highly purified steviol glycosides, particularly Rebaudioside D, are described. The methods include purification from the extraction stage of the Stevia rebaudiana Bertoni plant, purification of steviol glycoside mixtures, Rebaudioside D and Rebaudioside A from a commercial Stevia extract, and purification of Rebaudioside D from remaining solutions obtained... Agent:

20130071340 - Polyol partial esters for use in cosmetics: The invention relates to polyol partial esters, cosmetic and pharmaceutical formulations containing the polyol partial esters according to the invention, and to the use of the polyol partial esters according to the invention for cosmetic and pharmaceutical purposes.... Agent: Evonik Goldschmidt Gmbh

20130071341 - Sunscreen cosmetic: The present invention aims to provide a sunscreen cosmetic that does not contain diethylamino hydroxybenzoyl hexyl benzoate, can absorb a wide range of wavelengths of UV rays across the UVA and UVB regions, and prevent staining (dyeing) due to secondary adhesion to clothing. The present invention relates to a sunscreen... Agent:

20130071342 - Cosmetic composition comprising coumestrol or a bean extract containing coumestrol for skin care: The present invention relates to a cosmetic composition for skin care, comprising coumestrol or a bean extract containing coumestrol.... Agent: Amorepacific Corporation

20130071343 - Quaternary dialkanolamine esters: The invention relates to novel quaternary ammonium compounds of the esterquat type, to a method for the production thereof, and to the use thereof in formulations.... Agent: Evonik Goldschmidt Gmbh

20130071344 - Hair care composition: A hair care composition comprising: i) at least 1.6 wt % of the total composition of a group III or group IV metal salt or combination thereof; and ii) a charged polymer; and iii) a silicone; in which the composition has a pH of 4 or below at 20° C.... Agent:

20130071345 - Composition for hair care: A hair care composition that includes a combination of chemical mixture that includes a perfluororoalkylethyl acrylate/hema copolymer, butyl acetate, and an aliphatic isoparaffin; and further includes an added amount of an aliphatic isoparaffin. Most preferred is 15 wt % to 35 wt % of the chemical mixture that includes the... Agent: Namaste Laboratories, L.L.C.

20130071346 - Method for preparing personal care composition comprising surfactant system and high melting point fatty compound: Disclosed is a method of preparing a personal care composition, comprising a step of mixing a hot oil phase and a cold aqueous phase in a high shear field to form an emulsion, wherein the mixing step is conducted by using a homogenizer having a rotating member, wherein the oil... Agent:

20130071347 - Antimicrobial compositions: Antimicrobial compositions that include at least one aliphatic aldehyde component and allyl isothiocyanate are provided. Methods of reducing bacterial activity using the instantly disclosed compositions are also provided.... Agent: Takasago International Corporation

20130071348 - Nanoparticles with covalently bound surfactant for drug delivery: The present invention concerns nanoparticles, compositions comprising the nanoparticles, methods for their production, and methods of using the nanoparticles for the delivery of biologically active agents (e.g., antibiotics or other drugs) to human or non-human subjects. In one embodiment, the nanoparticle is a “surfactant-free” nanoparticle in which the surfactant moiety... Agent: University Of South Florida

20130071349 - Biodegradable polymers for lowering intraocular pressure: The present invention provides a method of treating glaucoma, the method comprising the step of placing a polymer in an eye of a patient, which biologically degrades over a period of time to release biodegradants, which are effective to lower the intraocular pressure of the patient, thereby treating glaucoma. Said... Agent: Allergan, Inc.

20130071350 - Method and compositions for treatment of cancers: The present invention refers to a system for inducing an immune response against transformed, infected, or diseased tissue comprising a device for removing only components present in blood or plasma having a molecular weight of 120,000 daltons or less, having an inlet and outlet for connection to a pump and... Agent: Biopheresis Technologies, Inc.

20130071352 - 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors: Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.... Agent: Idenix Pharmaceuticals, Inc.

20130071351 - Combination therapy: The invention provides combination treatments with IL-21, analogues and derivatives thereof. In particular, a combination comprising IL-21 and a monoclonal antibody and methods for using the combination in treating cancer are described.... Agent:

20130071353 - Antiviral compounds and methods of use thereof: Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.... Agent: Trana Discovery, Inc

20130071354 - Modulators of toll-like receptors: h

20130071355 - Recombinant herpes virus and pharmaceutical composition containing the same:

20130071365 - Induced hepatocytes: An object of the present invention is to produce hepatic cells from non-hepatic cells that can be obtained less invasively and at low cost. The gene of HNF3α, HNF3β, or HNF3γ and the gene of HNF4α are transduced into non-hepatic cells. The present invention enables the production of induced hepatocytes... Agent: Kyushu University, National University Corporation

20130071366 - Insulin-like growth factor ii (igf-ii) binding factors: This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified... Agent: Cancer Research Technology Limited

20130071367 - Animal feed for calves for conditioning the intestinal flora: The present invention is directed to a animal feed for calves comprising calf-specific bacteria, optionally lipids, proteins, vitamins and/or mineral materials for conditioning of the intestinal flora in calves, and thus, for prophylaxis and/or treatment of diarrhea in calves.... Agent: Technische Universitat Munchen

20130071368 - Preparation, use of preparation for treatment, and method of treatment of intestinal infection: A preparation for use in the treatment of clostridium difficile or salmonella infection comprising a mixture of galacto-oligosaccharide and matter from cranberry, and uses thereof.... Agent: Fayrefield Foods Limited

20130071356 - Treatment of plants against oomycete infection: p

20130071358 - Allogeneic microvascular tissue for soft tissue treatments: Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries.... Agent: Tornier, Inc.

20130071363 - Amnion-derived cells, methods of making and uses thereof: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived... Agent: Stemnion, Inc.

20130071364 - Amnion-derived cells, methods of making and uses thereof: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived... Agent: Stemnion, Inc.

20130071360 - Brown fat cell compositions and methods: Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods... Agent: Biorestorative Therapies, Inc.

20130071362 - Human placental collagen compositions, and methods of making and using the same: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.... Agent: Anthrogenesis Corporation

20130071357 - Identification, proliferation in situ, harvesting, separation, and transplantation of adult-derived regenerative pluripotent transitional blastomere-like stem cells and methods of treatment thereof: Non-embryonic transitional blastomere-like stem cells are disclosed. Most preferably, such cells are obtained from the blood after induction by a plant-based compound to proliferate and reverse diapadese into the vasculature or from various tissues of postnatal mammals or humans (using tissue biopsied from the mammal or human), are in the... Agent: Heygen, LLC

20130071359 - Methods and compositions for bone and cartilage repair: Biologically active extract of Hibiscus tiliaceus L. and compositions comprising the extract are described. The invention also provides therapeutic uses of the extract and compositions, in particular for promoting healing of bone and cartilage injuries, and the promotion of bone and cartilage formation.... Agent: Cimtech Pty Limited

20130071361 - Methods of treatment of hemophilia: The present invention provides methods of treating hemophilia in a subject, the methods comprising transplanting a therapeutically effective amount of bone marrow, cord blood, cord blood or bone marrow fraction expressing Factor VIII, mononuclear cells, or mesenchymal stromal cells from a donor to the subject with hemophilia. The present invention... Agent:

20130071370 - Inhibitors of micro-rnas for use for preventing and/or attenuating skin ageing and/or for hydrating skin: c. selecting the compounds for which an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the expression or an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the activity of at least one microRNA is measured in the... Agent: Chanel Parfums Beaute

20130071369 - Oral formulations for promoting cellular purification: An oral formulation includes a plurality of agents that promote cellular detoxification. Agents can be included that modulate expression of Nrf2-associated genes upon ingestion of the oral formulation by a subject, wherein the Nrf2-associated genes include at least one gene encoding intrinsic antioxidants, and at least one gene encoding cellular... Agent: Nse Products, Inc.

20130071372 - Metallo-protein and tocotrienol (mp-t3) compositions with non-protein-type metal chelator and uses thereof: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer... Agent: Naidu Lp

20130071371 - Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system: A composition and method of providing nitric oxide and nitrite therapy to patients whereby a therapeutic amount is bioavailable within approximately 30 minutes of administration. In embodiments of the invention, nitric oxide is produced in the oral cavity.... Agent: Board Of Regents Of The University Of Texas System

20130071373 - Methods for the diagnosis and therapy of retinitis pigmentosa: The present invention relates to a method of identifying a subject having or at risk of having or developing a retinitis pigmentosa, comprising detecting in a sample obtained from said subject, the presence of at least one mutation in the rhodopsin (RHO) gene selected from the group consisting of c.263T>C,... Agent:

20130071374 - Rna interferases and methods of use thereof: The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to... Agent: University Of Medicine And Dentistry Of New Jersey

20130071375 - Compositions and methods for treating inflammation: The present invention provides methods for treating sepsis comprising administering to an individual an effective amount of a chimeric protein.... Agent: Saint Louis University

20130071376 - Bathing composition and method for preparing same: The present invention relates to a composition for bath additives characterized in that the composition is obtained by a process comprising subjecting herbal materials comprising 10˜25% by weight of Zizania latifolia, 10˜20% by weight of Artemisia capillaries, 5˜15% by weight of Houttuynia cordata, 1˜20% by weight of Saururus chinensis, 1˜15%... Agent:

20130071377 - Composition for increasing milk production containing artemisia capillaris: The present invention relates to a composition for increasing the milk production of livestock, containing Artemisia capillaris as an active ingredient. More specifically, relates to a composition and a feed additive for increasing the milk production of cows, containing Artemisia capillaris as an active ingredient, and a composition and a... Agent: Rnl Bio Co., Ltd

20130071378 - Sir2 activity: Methods for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound are described.... Agent:

20130071379 - 1b20 pcsk9 antagonists: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host... Agent:

20130071384 - Antibody formulations: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).... Agent: Genentech, Inc.

20130071382 - Egfr mutations: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated... Agent:

20130071381 - Humanized anti-ccr2 antibodies and methods of use therefor: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of... Agent:

20130071386 - Immunoglobulin formulation and method of preparation thereof: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of... Agent:

20130071390 - Method for preparing antibodies having improved properties: The present invention is directed to methods and compositions for the production of Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc region.... Agent: Merck, Sharp & Dohme Corp

20130071388 - Method for treating psoriasis: Methods and compositions are provided for the creation and screening of non-human animal models having many of the histologic characteristics of human psoriasis. Immunocompromised host animals are injected with a purified population of CD45Rb positive cells, which are tolerant of the host major histocompatibility antigens, but are mismatched at one... Agent: Abbott Biotherapeutics Corp.

20130071389 - Methods for treatment of inflammatory diseases: The present invention provides methods of treating inflammatory diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits pigment epithelium-derived factor (PEDF) and methods of screening for agents that inhibit PEDF.... Agent: The Feinstein Institute For Medical Research

20130071380 - Modulation of pilr to treat immune disorders: The present invention provides methods of using PILRα agonists, or PILRβ antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation.... Agent: Schering Corporation

20130071385 - Monoclonal antibodies: The invention provides heterochimeric antibodies and/or fragments thereof comprising (i) hypervariable region sequences wholly or substantially corresponding to sequences found in antibodies from a donor species; (ii) constant region sequences wholly or substantially corresponding to sequences found in antibodies from a target species which is different from the donor species;... Agent:

20130071387 - Pharmaceutical formulations: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.... Agent: Amgen Inc.

20130071383 - Selective modification of proteins: A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a... Agent: Novo Nordisk A/s

20130071394 - Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use: Provided are compositions and combinations containing an organophosphorus bioscavenger and a hyaluronan-degrading enzyme. The provided compositions and combinations can be used to treat or prevent organophosphorus poisoning, including nerve agent poisoning and pesticide poisoning.... Agent:

20130071395 - Compositions and methods for treating pathologies: A composition for treating a neoplastic disorder includes an activatable cell penetrating peptide coupled to antibody and/or fragment thereof to an essential gene product of a neoplastic cell.... Agent: Case Western Reserve University

20130071393 - Methods for increasing red blood cell levels and treating anemia using a combination of gdf traps and erythropoietin receptor activators: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.... Agent: Acceleron Pharma, Inc.

20130071391 - Methods of treating glucose metabolism disorders: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.... Agent:

20130071392 - Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides small heat shock protein activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease.... Agent:

20130071396 - Method of inhibiting coagulation activation with human anti-factor v antibodies and use thereof: The present invention also discloses the novel use of factor Va inhibitors in the treatment of various disorders caused by the formation of blood clots.... Agent:

20130071399 - Immunogen and antivenom against violin spider venom: The invention relates to the isolation, characterisation and expression of DNA fragments encoding sphingomyelinases D from three species of Loxosceles genus spiders, namely L. boneti., L. reclusa and L. laeta, and the toxoids thereof. The invention also relates to the production of active sphingomyelinases D and the toxoids thereof using... Agent: Universidad Nacional Autonoma De Mexico

20130071397 - Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof: The present invention provides moieties that bind to the most membrane-proximal Ig-like domain of the ectodomain (D7) of vascular endothelial growth factor (VEGF) receptors, wherein the moieties antagonize the activity of the VEGF receptor.... Agent: Yale University

20130071400 - Lingo binding molecules and pharmaceutical use thereof: The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which... Agent: Novartis Ag

20130071401 - Methods of treating diabetes and compositions capable of same: A composition of matter is disclosed which comprises isolated oligomers of human islet amyloid polypeptide (IAPP). Antibodies recognizing same are also disclosed. Use of the composition of matter and the antibodies are also disclosed.... Agent: Ramot At Tel-aviv University Ltd.

20130071398 - Pharmaceutical composition for treating and/or preventing cancer: According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing cancer is provided. Specifically, the present invention provides a pharmaceutical... Agent: Toray Industries, Inc.

20130071402 - Pharmacogenetic test anti-resorptive therapy-associated osteonecrosis of the jaw: The present invention relates to methods and compositions for testing individuals to determine whether they are at increased risk of developing anti-resorptive therapy-associated osteonecrosis of the jaw.... Agent: The Trustees Of Columbia University In The City Of New York

20130071403 - Synergistic anti-tumor efficacy using alloantigen combination immunotherapy: The present disclosure provides combinations of immunotherapeutics and methods for treating medical conditions that are characterized by the lack of an effective immune response, for example as would result following a down-regulation of MHC class I, such as in cancer. The immunotherapeutic compositions of the invention, which can be used... Agent: Vical Incorporated

20130071404 - Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or... Agent: Critical Care Diagnostics, Inc.

20130071405 - Antibodies to pcsk9 and uses thereof: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.... Agent: Eli Lilly And Company

20130071406 - Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments: The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as... Agent: Immunomedics, Inc.

20130071410 - Human cgrp receptor binding proteins: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R... Agent:

20130071411 - Iap bir domain binding compounds: t

20130071409 - Icos critically regulates the expansion and function of inflammatory human th17 cells: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T... Agent: The Trustees Of The University Of Pennsylvania

20130071408 - Methods for diagnosis and treatment of non-insulin dependent diabetes mellitus: Methods and compositions are provided for the treatment and diagnosis of diseases related to hyperglycemic conditions, including diabetes, insulin resistance, and the like. Genetic polymorphisms are shown to be associated with disease susceptibility, and their detection is used in the diagnosis of a predisposition to these conditions. The corresponding proteins... Agent:

20130071407 - Methods for modulating hematopoiesis and vascular growth: This application pertains to methods and compositions that modulate proliferation and/or differentiation of undifferentiated mesodermally-derived cells so as to have an effect on at least one of vascular growth and hematopoiesis.... Agent: President And Fellows Of Harvard College

20130071412 - Methods and compositions for stable liquid drug formulations: The invention features a powdered composition including a pharmaceutically active compound and a protein or a hydrolyzed protein. In particular, the powdered composition forms a stable solution or dispersion suitable for oral administration in which the protein or the hydrolyzed protein is bound to the pharmaceutically active compound. The invention... Agent: Exodos Life Sciences Limited Partnership

20130071413 - Targeted immune conjugates: Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of immunogens to the reticuloendothelial system via non-circulating lymphoid cells are provided.... Agent: Augmenta Biologicals, LLC

20130071414 - Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies: The present invention generally concerns particular methods and compositions for cancer therapy. In particular embodiments, there methods and compositions related to cells that harbor expression vectors encoding a cytokine and an inducible suicide gene and, optionally, the same or different vector(s) encoding a chimeric antigen receptor and/or a detectable gene... Agent:

20130071415 - Heterocyclic compounds as janus kinase inhibitors: or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using... Agent: Biocryst Pharmaceuticals, Inc.

20130071416 - Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae: The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS)... Agent: Novartis Ag

20130071417 - N-domain of carcinoembryonic antigen and compositions, methods and uses thereof: The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer.... Agent: Governing Council Of The University Of Toronto

20130071418 - Physicochemical (pcp) based consensus sequences and uses thereof: Provided herein is a computational method for designing a PCP-consensus protein for a family of related proteins. The method uses a consensus alignment of a protein domain common to all the related proteins, which may or may not be substantially biased, from which an average value of p, e.g., 5,... Agent: The Board Of Regents Of The University Of Texas System

20130071419 - Universal dengue virus sequences and methods of use: Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments (such as the E protein ectodomain and DIII domain) fused to the molecular adjuvant P28. The disclosed nucleic acid and polypeptide sequences can be... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20130071420 - Yeast-based vaccines as immunotherapy: Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle... Agent: Globeimmune, Inc.

20130071422 - Adjuvanted vaccines for serogroup b meningococcus: An immunogenic composition comprises (i) an immuno stimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex, and (ii) a meningococcal serogroup B antigen. In most embodiments, the composition does not include an aluminium salt and does not include... Agent:

20130071421 - Turkey viral hepatitis virus and uses thereof: Isolated a Turkey Viral Hepatitis picomavirus-like viruses associated with Turkey viral hepatitis, and isolated nucleic acid sequences and polypeptides are disclosed. Antibodies against antigens from Turkey Viral Hepatitis picornavirus-like viruses, iRNAs which target nucleic acid sequences of the Turkey Viral Hepatitis picornavirus-like virus, methods for detecting the presence or absence... Agent:

20130071423 - Combination vaccine for streptococcus: The invention relates to the use of a combination of SP1298 and SP2205 proteins or functional fragments thereof or homologous proteins or protein fragments thereof of S. pneumoniae for preventing or treating a S. pneumoniae infection, their use for the preparation of a vaccine for the preventive treatment of a... Agent: Stichting Katholieke Universiteit

20130071424 - Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein: The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who... Agent: New York University

20130071425 - Bio-pesticide and method for pest control: The present invention relates to a new method for pest control and/or for preventing or treating pest infestation. Said method comprises the inoculation of plants, parts of plants or the surrounding of said plants with an effective amount of endophytic Beauveria bassiana strains. In a further aspect the present invention... Agent:

20130071426 - Topical pharmaceutical or cosmetic composition useful for the treatment of diseases or conditions that transcur through a deficit of maturation of the cornified envelope: It comprises a combination of glycerin, niacinamide, and an extract of Fucus Serratus, to topical pharmaceutical or cosmetic compositions containing them, processes for their preparations, as well as their pharmaceutical use in the prophylaxis and/or treatment of disease or conditions that transcur through a deficit of maturation of the cornified... Agent: Laboratorios Leti, S.l.

20130071427 - Kit of parts for treating and/or preventing cutaneous ulcers: The present invention regards a kit of parts for treating and/or preventing cutaneous ulcers, preferably chronic ulcers, such as for example decubitus ulcers, even more preferably trophic ulcers of the lower limbs, and for treating and/or preventing cutaneous ulcers caused by the Herpes simplex virus, preferably lip ulcers, or cutaneous... Agent:

20130071428 - Peptides, conjugates and method for increasing immunogenicity of a vaccine: The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and... Agent: Academisch Ziekenhuis Leiden H.o.d.n. Lumc

20130071429 - Bunyavirus vaccine: The present invention provides attenuated viruses for use as vaccines and for the treatment and/or prevention of viral diseases and/or infections.... Agent: University Court Of The University Of St Andrews

20130071431 - Method for preserving polypeptides using a sugar and polyethyleneimine: The invention relates to the preservation of an active agent, such as a polypeptide, by contacting the active agent with a preservation mixture including a sugar and polyethyleneimine.... Agent: Stabilitech Ltd.

20130071430 - Microrna-controlled recombinant vaccinia virus and use thereof: It is intended to provide a vaccinia virus that specifically proliferates in a cancer cell and destroys the cancer cell and to provide use of the virus in cancer treatment. The present invention provides a microRNA-controlled vaccinia virus, in which a target sequence of a microRNA less expressed in a... Agent: The University Of Tokyo

20130071432 - Combination virotherapy for cancer: One aspect of the present disclosure relates to a method for treating a subject with cancer. The method includes administering an oncolytic virus simultaneously, sequentially, or separately in combination with an immunomodulatory agent in an amount effective to suppress both antiviral immunity and angiogenesis associated with the cancer.... Agent: The Cleveland Clinic Foundation

20130071434 - Campylobacter polypeptides and methods of use: The present invention provides isolated metal regulated polypeptides obtainable from a Campylobacter spp., and compositions including the polypeptides. The present invention also includes methods for using the compositions disclosed herein, including methods for treating in infection in a subject, for treating a condition caused by a Campylobacter spp., and for... Agent: Epitopix LLC

20130071433 - Interferon-ß production modulating listeria strains and methods for using same: Mutant Listeria bacteria that modulate interferon-B production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a TetR gene, a LadR gene, a VirR gene, a MarR gene a MdrL gene, a MdrT gene and a MdrM gene. The subject bacteria find use... Agent:

20130071437 - Immunological function enhancing agent: An agent, as an active ingredient thereof, includes activated lymphocytes derived from a tissue of an animal, in which antibodies and immunocytes do not pass from a mother to a fetus across the placenta, and which is used to enhance the immunological functions of another animal of the same species... Agent: Canine-lab.inc.

20130071435 - Novel herbal formulation for the modulation of immune system of hiv infected patients and a process of preparation thereof: An herbal formulation for the modulation of immune system of HIV infected patients and a process of preparation thereof are provided. The process includes (i) preparing a hydromethanolic extract of at least one plant selected from Hippophae rhamnoides, Convolvulus pluricaulis, Withania somnifera, Ocimum sanctum, and Cynodon dactylon at 80-90° C.,... Agent: Sunil Kumar Swamy Rajan And Arun Kumar Swamy Rajan

20130071436 - Treatment of t-cell mediated diseases: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides... Agent: Dmi Biosciences, Inc.

20130071442 - Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between... Agent:

20130071444 - Amphiphilic cationic polymers and methods of use thereof: Amphiphilic cationic polymers comprising a biocompatible amphiphile linked to an organic cation are provided. The polymers complex with therapeutic agents and facilitate delivery of such therapeutic agents, particularly therapeutic nucleic acids, both in vitro and in vivo. Accordingly, the invention further provides methods of facilitating delivery of therapeutic and/or diagnostic... Agent: The Charlotte-mecklenburg Hospital Authority D/b/a Carolinas Healthcare System

20130071451 - Carotenoid-containing composition and production method thereof: A method of producing a carotenoid-containing composition including: obtaining a carotenoid-containing oil phase composition by heating an oil phase component mixed liquid containing a carotenoid component containing at least one crystalline carotenoid, and a (poly)glyceryl fatty acid ester having form 1 to 6 of a glycerin unit and from 1... Agent: Fujifilm Corporation

20130071441 - Cell construct for cell transplantation and cell aggregate for cell transplantation: An object of the present invention is to provide a cell construct for cell transplantation capable of having a thickness suitable for cell transplantation, preventing the necrosis of transplanted cells, and forming blood vessels in the transplantation site after transplantation. The present invention provides a cell construct for cell transplantation... Agent: Fujifilm Corporation

20130071449 - Coatings of acrylamide-based copolymers: An implantable device including a conjugate formed of an acrylamide-based copolymer and a bioactive agent is provided.... Agent: Abbott Cardiovascular Systems Inc.

20130071438 - Compositions and methods for the treatment of hyperplasia: In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically... Agent:

20130071450 - Gels for transdermal delivery: The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.... Agent: Covidien Lp

20130071443 - Glycosaminoglycans: Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and/or development and/or regeneration of tissue.... Agent: Agency For Science, Technology And Research

20130071446 - Infant nutrition for improving fatty acid composition of brain membranes: The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes.... Agent:

20130071439 - Methods and compositions for treating biofilms: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using D-amino acids are described.... Agent: President And Fellows Of Harvard College

20130071447 - Methods for producing ecm-based biomaterials: A method for forming an extracellular matrix material (ECM) material includes providing at least an ECM composition containing ECM particles varying in their capacity for migration through a fluid medium, including at least one population of expanded ECM particles. The ECM composition is combined in a fluid medium to form... Agent: Cook Medical Technologies LLC

20130071452 - Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof: The present invention relates to a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof, and an acidic additive. This composition, owing to improved stability even after a long-term storage, is suitable for inhibiting the growth of cancer cells.... Agent: Hanmi Science Co., Ltd

20130071445 - Transluminal drug delivery methods and devices: Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense... Agent: Kalium, Inc.

20130071448 - Treatment of t-cell mediated diseases: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides... Agent: Dmi Biosciences, Inc.

20130071440 - Use of simple amino acids to form porous particles: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter... Agent: Civitas Therapeutics, Inc.

20130071454 - Breath freshening confectionery products and methods of making and using same: A confectionery product comprises a first side and a second side generally opposite to the first side; the second side comprising an abrasive surface that is suitable for scrubbing the top surface of a tongue within the oral cavity. In preferred embodiments the first side is smooth, and may be... Agent: Wm. Wrigley Jr. Company

20130071453 - Compositions comprising solid particles entrapped in collapsed polymeric microspheres, and methods of making the same: The present invention relates to topical compositions containing solid particles that are stabilized via entrapment by microspheres and methods for making the same. Each of the microspheres contains a collapsed polymeric shell that has entrapped therein one or more solid particles. The solid particles are preferably formed of zinc oxide... Agent:

20130071456 - Encapsulation of ingredients in lactose matrix to form active encapsulates: An oral care composition and method are described in which the composition includes lactose matrix encapsulates entrained in a carrier. The encapsulates may further comprise oral care and/or personal care ingredients.... Agent: Colgate-palmolive Company

20130071455 - Solid core coacervated capsules: Coacervated capsules that have from 10 to 99% by weight of the capsule of a core comprising a mixture of (I) a fatty component of (i) hydrogenated oil or (ii) hydrogenated fat or (iii) cocoa butter or (iv) a mixture thereof and (II) a material to be encapsulated comprising a... Agent: Firmenich Sa

20130071457 - Wound healing device: The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix.... Agent: Stemnion, Inc.

20130071458 - Active agents and their oligomers and polymers: Conjugates comprising at least two active agents linked by a diglycolic acid or polyglycol diacid linker are disclosed. The invention also concerns oligomers and polymers of these conjugates and their use in therapeutic and industrial applications for localized, immediate or fast release delivery of an active agent, such as an... Agent:

20130071459 - Formulations employing anhydrous disinfectant: Use of dried compositions of silver dihydrogen citrate along with citric acid in antimicrobial amounts directly as disinfectants is described.... Agent: Pure Bioscience

20130071461 - Methods employing anhydrous disinfectant: Use of dried compositions of silver dihydrogen citrate along with citric acid in antimicrobial amounts directly as disinfectants is described.... Agent: Pure Bioscience

20130071460 - Novel pesticidal composition: The present invention relates to an agricultural composition comprising sulphur in the range from 20% to 80% of the total composition, a chloronicotinyl compound in the range from 0.7% to 25% of the total composition, a pyrethroid compound in the range from 0.75% to 10% of the total composition and... Agent:

20130071462 - Drug delivery systems and applications: Certain embodiments of the invention include medical materials and methods comprising a biodegradable hydrophilic hydrogel comprising dispersed lipophilic particles that comprise a therapeutic agent, wherein the lipophilic particles have a low water solubility in physiological saline at physiological temperature.... Agent:

20130071463 - Implants for postoperative pain: Medical implants and methods useful in treating postoperative pain are described. The implants comprise one or more electrospun drug-loaded fibers, which fibers comprise a drug useful in the treatment of pain. The implants are implanted at sites of interest including joint capsules, bones, and subcutaneous spaces, and are secured with... Agent:

20130071464 - Composition comprising phosphonic acid polymer for use as tissue engineering fibrous scaffold: A fibrous tissue scaffold wherein fibres of the scaffold comprise a phosphonic acid polymer. The fibres preferably incorporate a vinylphosphonic acid—acrylic acid copolymer, and may further include polycaprolactone. There is further described medical implant coating comprising a phosphonic acid polymer, a biocompatible fibre comprising a phosphonic acid polymer and a... Agent: The University Of Manchester

20130071465 - Activated leukocyte composition and uses for wound healing: Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.... Agent: Macrocure Ltd.

20130071470 - Fenugreek seed extract to lower blood cholesterol: A method of lowering blood cholesterol in a non-diabetic patient by at least 30% is described. The method involves orally administering for 30 consecutive days a fenugreek seed extract composition. Various methods of preparation and various formulations are described. Physiologically effective pharmaceutical compositions and beverages containing fenugreek seed extracts and... Agent:

20130071468 - Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and... Agent: Insmed Incorporated

20130071469 - Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and... Agent: Insmed Incorporated

20130071466 - Methods and compositions for treating gastric disorders: Improved efficacy in treatment of gastric disorders with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for topical administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by application onto the surface of the tissue within... Agent: Lipella Pharmaceuticals Inc.

20130071471 - Pharmaceutical composition for treating atopic dermatitis: A method of treating mild atopic dermatitis patients by locally administering an external composition containing adenosylcobalamin as an active ingredient is provided. The composition can effectively treat mild atopic dermatitis patients without side effects.... Agent: Hanall Biopharma Co., Ltd.

20130071467 - Retinoid-liposomes for treating fibrosis: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ... Agent:

20130071472 - Fascile synthesis of biocompatible polymer capsule nanoparticles for drug encapsulation: The present invention relates to a method for preparing a capsule nanoparticle used in encapsulating hydrophobic medicines, comprising the following steps: (A) providing a biocompatible polymer and an organic solution containing a hydrophobic medicine; (B) stirring the organic solution at 3-10° C., and titrating with an alcohol solution, so as... Agent:

20130071473 - Composition and method for treating ulcers: The composition for the treatment of ulcers includes ground charcoal, ground mustard seed and an edible salt dissolved or suspended in an edible oil. A single effective therapeutic dosage of the composition includes approximately 4,000 mg of the ground charcoal, approximately 2,500 mg of the ground mustard seed, approximately 550... Agent:

20130071474 - Combinations of berberine, artemisinin, loperamide and their derivatives to treat malaria, diarrhea, travelers' diarrhea, dysentery, dengue fever, parasites, cholera and viruses: This invention relates to compositions and methods of combining berberine, artemisinin and loperamide or their derivatives in a therapeutic product for mammals suffering from malaria, diarrhea, travelers' diarrhea, dysentery, dengue fever, parasites, cholera and viruses by administration of a therapeutically effective amount of the composition.... Agent:

20130071475 - Method for producing an oral pharmaceutical form with immediate disintegration and active ingredient release: The invention relates to a method for producing an oral form of administration which decomposes immediately and releases active ingredients in the mouth. According to said method, (a) an anionic pharmaceutical active ingredient is intensively mixed with (b) a copolymer consisting of radically polymerized C1-C4 esters of the acrylic acid... Agent:

20130071477 - New abuse-resistant pharmaceutical composition for the treatment of opioid dependence: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles... Agent: Orexo Ab

20130071476 - Rapid melt controlled release taste-masked compositions: Rapid melt tablets that dissolve and release an active component in the oral cavity are comprised of a pharmaceutical active ingredient such as dextromethorphan complexed with a resin that is effective in taste-masking the otherwise bitter taste of the active making it convenient for oral administration. The drug/resin-complexed particles can... Agent:

20130071478 - Retinoid-liposomes for enhancing modulation of hsp47 expression: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1—2 (SEQ ID NOS: 60 and 127), SERPINH1—45a (SEQ ID NOS: 98 and 165), and SERPINH1—51 (SEQ... Agent:

20130071479 - Microspheres: The disclosure relates to substantially uniform, high density microspheres and methods of making the microspheres. The microspheres can be made to be small in size with a narrow range of particle size distribution and a high sphericity. In one aspect, the microspheres provided herein are provided in the form of... Agent: Grain Processing Corporation

20130071480 - Particles which are surface coated with hyaluronan or one of the derivatives thereof and the use of same as biological vectors for active substances: Particles having a core based on at least one biodegradable organosoluble polymer. At least a part of the surface of the particles is coated with at least one hyaluronan or a derivative thereof, the hyaluronan being a water-soluble, amphiphilic hyaluronan of which the carboxylic functions are in part transformed to... Agent: Centre National De La Recherche Scientifique

20130071481 - Coated particle and method for producing coated particle: The present invention relates to a coating particle containing a nuclear particle covered with a coating layer, and in the coating particle, the coating layer is a layer containing hydroxyalkyl cellulose and a binder.... Agent: Kobe Gakuin Educational Foundation

20130071482 - Block copolymer cross-linked nanoassemblies as modular delivery vehicles: A nanoassembly includes a core protected by a biocompatible shell. The nanoassembly includes a plurality of block copolymers including drug-binding linkers and block copolymer cross-linkers. A first active agent is covalently conjugated to the plurality of block copolymers and a second active agent is physically entrapped in the core.... Agent: The University Of Kentucky Research Foundation

20130071483 - Vaccine produced using optimized immobilization antigen cdna of cryptocaryon irritans and producing method and use thereof: The present invention provides an optimized immobilization antigen cDNA sequence of cryptocaryon irritans, which has been processed codon replacement and caused the cDNA to express in prokaryotic and eukaryotic cell and translate a protein has similar immunogenicity as the immobilization antigen purified from the theront of Cryptocaryon irritans. The present... Agent: National Taiwan University

20130071484 - Self-assembled toroidal-spiral particles and manufacture and uses thereof: Toroidal-spiral shaped particles, their method of manufacture, and uses thereof are disclosed. The toroidal-spiral particles can contain at least one active agent, such as a drug, and provide a controlled, sustained release of the active agent.... Agent: The Board Of Trustees Of The Univeristy Of Illinois

20130071485 - Organic lubricant: A vaginal lubricant of primarily organic materials has excellent properties for relieving vaginal dryness.... Agent:

20130071486 - Acellular tissue matrices made from alpha-1,3-galactose-deficient tissue: The invention provides acellular tissue matrices made from collagen-containing tissues of animals genetically modified so as to be deficient in the galactose 1,3-galactose epitope and methods of making and using such acellular tissue matrices.... Agent: Lifecell Corporation

20130071487 - Xenon-based inhalable drug for preventing addiction relapses in humans: The invention relates to a gas composition containing xenon gas for use in preventing the relapse of a patient who has been weaned from at least one psychotropic product which resulted in said patient becoming habituated, the xenon being administered to the patient by inhalation. The composition of the invention... Agent: L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude

20130071488 - Disinfectant composition for hard articles, and method for disinfecting of surface of hard article: Disclosed are a two-agent type disinfectant composition for hard articles, which includes a first agent containing a powder mixture (A) and a second agent containing an aqueous hydrogen peroxide solution (B-1), the powder mixture (A) containing an alkali metal salt (A-1) exhibiting basicity when the salt is in the form... Agent: Lion Corporation

20130071489 - Methods and compositions for safe and effective treatment of erythema: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.... Agent: Galderma Research & Development Snc

20130071490 - X-ray contrast media compositions and methods of using the same to treat, reduce or delay the onset of cns inflammation and inflammation associated conditions: Embodiments disclosed herein relate to improved X-ray contrast media compositions and methods of using the same for treating symptoms related to allergic reactions, inflammatory conditions, symptoms of the common cold and certain cancers.... Agent:

20130071491 - Extruded legume food products containing yeast autolysate: An extrusion process for producing a uniform and highly expanded food product is disclosed with nutritional yeast and chromium. The uniform expansion ratio possessed by the extruded product provides a consistent texture and has application in a wide variety of food consumables, ranging from snacks to breakfast cereals.... Agent:

20130071492 - Systems and methods for generating germicidal compositions: The present invention relates to systems and methods for generating germicidal compositions for use in a wide variety of settings, including agricultural settings, food production settings, hospitality settings, health care settings, health club settings, exercise facility settings, research based settings, veterinarian settings, medical settings, hydraulic fracturing settings, and/or any setting... Agent:

20130071493 - Dietary supplement containing alkaline electrolyte butters: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the... Agent:

20130071494 - Nitrite formulations and their use as nitric oxide prodrugs: Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt.... Agent:

20130071496 - Controlled release composition containing a strontium salt: A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for... Agent: Osteologix A/s

20130071495 - Inhibitors of glycogen synthase kinase 3 for use in therapeutic methods and screening method relating thereto: The present invention relates to an inhibitor of glycogen synthase kinase 3 (GSK-3) for use in a method of treating or preventing emphysema, a method of activating an emphysema cell, an activated emphysema cell obtained by this method for use in a method of treating or preventing emphysema, and a... Agent: Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (gmbh

20130071497 - Formulations and methods for preventing eyebrow hair loss: Compositions comprising from about 0.5 to about 40 percent by weight of black cohosh extract, from about 0.5 to about 20 percent by weight of nonionic surfactant, and from about to 40 about 99 percent by weight of hydroxylated solvent are effective in reducing and preventing eyebrow hair loss in... Agent: Rmv Trademarks, LLC

20130071498 - Insecticidal compositions and uses thereof: The present invention provides compositions and methods for controlling plant pests. In particular, the present invention provides plant extracts with insecticidal activity.... Agent: Board Of Trustees Of Michigan State University

20130071499 - Composition for treating inflammatory, allergic or asthma diseases, containing paprika extracts: The present invention relates to a composition containing a paprika extract as an active ingredient, and more particularly to a pharmaceutical composition or health functional food for preventing or treating inflammatory, allergic or asthma disease, which contains a paprika extract. Particularly, paprika is a natural food which is readily available... Agent: Industry-university Cooperation Foundation Hanyang University

20130071500 - Compositions and methods for treating signs of skin aging: The invention relates to methods and compositions for treating skin aging, said compositions comprising at least one tropoelastin promoter and at least one tropoelastin crosslinker.... Agent: Johnson & Johnson Consumer Companies, Inc.

20130071501 - Extract of stewartia koreana and use thereof: The present invention relates to an extract of Stewartia koreana and use thereof More particularly, it relates to an extract of Stewartia koreana which is extracted with any one selected from the group consisting of water, a C1-4 low alcohol, a polar solvent, a non-polar solvent and a mixture thereof,... Agent: Rna, Inc.

20130071502 - Compositions for skin disease or disorders: Medicaments or cosmetic compositions for the treatment or alleviation of skin or mucous membrane diseases or disorders related to an enhanced level of anti-microbial peptides or proteins comprising Tambourissa plant extracts, which may comprise polyphenols.... Agent: Bayer Consumer Care Ag

20130064759 - Copolymer-stabilized emulsions: An emulsion includes a substantially continuous liquid medium, and a plurality of droplet structures dispersed within the substantially continuous liquid medium. Each droplet structure of the plurality of droplet structures includes an outer droplet of a first liquid having an outer surface; an inner droplet of a second liquid within... Agent: The Regents Of The University Of California

20130064760 - Method for treating crohn's disease by administering an anti-il-12 antibody: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as Crohn's disease.... Agent: Janssen Biotech, Inc.

20130064763 - Anti-icam-1 single domain antibody and uses thereof: Anti-ICAM-1 VHH single-domain antibodies (sdAbs) are generated by immunizing a llama with recombinant ICAM-1. These antibodies are linked to an imaging moiety for in vivo or ex vivo imaging of ICAM-1-related pathological conditions including atherosclerotic plaques. The antibodies may also be linked to a therapeutic agent to specifically target and... Agent: National Research Council Of Canada

20130064761 - Methods for the treatment of tumors expressing tat123 or naturally occurring variants thereof: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent:

20130064762 - Methods of detecting and treating cancers using autoantibodies: This invention generally relates to a method of identifying pre-neoplastic or neoplastic tissue of a mammal by utilizing autoantibodies that detect the pre-neoplastic or neoplastic tissue. Also described herein are methods of killing pre-neoplastic or neoplastic tissue by either binding toxins to autoantibodies that detect the pre-neoplastic or neoplastic tissue... Agent: The Rockefeller University

20130064764 - Miniaturized 62zn/62cu generator for high concentration clinical delivery of 62cu kit formulation for the facile preparation of radiolabeled cu-bis(thiosemicarbazone) compounds: A new system accomplishes easy, interchangeable production of multiple PET radiopharmaceuticals through the use of a simplified eluant-only generator and a kit based synthesis technique employing lyophilized or freeze dried ligand. Thus, by simply switching the lyophilized ligand vial kit, any number of 62Cu-labeled radiopharmaceuticals (62Cu-ligand) can be interchangeably synthesized... Agent:

20130064765 - Antithrombotic nanoparticle: The present invention encompasses an antithrombotic nanoparticle.... Agent: The Washington University

20130064766 - Tricarbonyl technetium-99m or rhenium-188 labeled cyclic rgd derivatives, a preparation method thereof, and a pharmaceutical composition containing the derivatives as an active ingredient for use in the diagnosis or treatment of angiogenesis-related disea: The present invention relates to tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment (radiotherapy) of angiogenesis-related diseases. The tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives of the... Agent: Snu R&db Foundation

20130064767 - Imaging infection with compounds that bind to thymidine kinase: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound,... Agent: The Johns Hopkins University

20130064768 - Lipophilic cationic probe for pet-imaging: The present invention provides an imaging probe which comprises a lipophilic cation, a hydrophobic moiety and a PET nucleus. The present invention also provides a precursor molecule for the production of such an imaging probe and methods for using the probe for analysing mitochondrial membrane potential in a subject.... Agent: Cambridge Enterprise Limited

20130064769 - Methods and apparatus for synthesizing imaging agents, and intermediates thereof: The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., 18F). Various embodiments of the invention may be useful... Agent: Lantheus Medical Imaging, Inc

20130064770 - Radiolabeled compounds and methods thereof: The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also... Agent: Ge Healthcare Limited

20130064772 - Infection activated wound caring compositions and devices: Provided are wound caring compositions and devices containing a pH-sensitive, preferably acid degradable, components contained in a water-permeable and hydronium ion permeable material. The pH-sensitive component encloses an antibiotic which is released to the wound upon infection by a microorganism at the wound site, and/or encloses a pH indicator. The... Agent: Indicator Systems International, Inc.

20130064771 - Photoacoustic matching material: A photoacoustic matching material includes water, a thickener, and a light scattering member.... Agent: Canon Kabushiki Kaisha

20130064773 - Drug-containing implants and methods of use thereof: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia... Agent:

20130064774 - Methods and compositions for maintenance of a functional wound: The present invention relates to methods and compositions for the modulation of wound healing and/or the production of extracellular membrane components by modulating the activity and/or amount of secreted protein acidic and rich in cysteine (SPARC) protein. The invention further provides methods for identifying compounds useful in the above-mentioned methods... Agent: Singapore Health Services Pte. Ltd.

20130064775 - Use of riluzole for treating or preventing the adverse effects of antineoplastic agents: This invention relates to riluzole for use in the treatment or prevention of adverse effects associated with the administration of anticancer agents having neurotoxic effects, such as, for example, platinum salts, taxanes and periwinkle alkaloids.... Agent: Universite D'auvergne Clermont I

20130064776 - Labelled silica-based nanomaterial with enhanced properties and uses thereof: The present invention relates to labelled silica-based nanoparticles with enhanced properties, to process for preparing them and to uses thereof.... Agent: Centre National De La Recherche Scientifique

20130064777 - Surfactant-free water-free foamable compositions, breakable foams and gels their uses: A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a... Agent: Foamix Ltd.

20130064778 - Oral hygiene products and method: The present invention is directed towards a composition for highly efficient and quick plaque and tartar removal and inhibition including pure ascorbic acid crystals and/or granulars (vitamin C) and an enamel repairing composition such as hydroxyapatite. The composition can contain from about 10% up to 90% of ascorbic acid without... Agent: Dentech, Inc.

20130064779 - Oral care compositions resistant to microbial growth: Described herein are compositions which prevent the growth of bacteria resistant to high salt concentrations, methods of preparing the same, and methods of using the same.... Agent: Colgate-palmolive Company

20130064780 - Compositions comprising avermectin/azelaic acid compounds useful for treating e.g., rosacea: Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor.... Agent: Galderma S.a.

20130064782 - Cosmetic composition comprising a bitter compound, a fragrance, an extract of stevia and a salt: a

20130064781 - Method for masking the bitterness of a uv-screening agent: The sweetener may advantageously be used in combination with a mint aroma or a salt, for example sodium chloride. This mixture of sweetener with a second gustatory agent makes it possible to mask the bitterness of the hydrophilic UV-screening agent without changing the nature of the fragrance or the colour... Agent: Lvmh Recherche

20130064783 - Boron-containing small molecules: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part... Agent: Anacor Pharmaceuticals, Inc.

20130064784 - Treatment composition: A concentrated treatment composition includes a bird repelling composition, a glycol, and a fragrance-containing/odor control composition. The concentrated treatment composition provides a stable product that is miscible with water. Methods for applying to the treatment compositions are also provided.... Agent: Avian Enterprises, LLC

20130064785 - Skin treatment composition: The invention is in the field of skin hygiene, especially hand hygiene and/or hand soap compositions. It remains to be desired to prepare skin hygiene compositions having a high anti-microbial effect, even with a low dosage of anti-microbial essential oils. It is therefore an object of the invention to provide... Agent:

20130064786 - Sirna hydrogel and method for manufacturing the same: The present invention relates to siRNA hydrogel and a method for manufacturing the same, and more particularly, to siRNA hydrogel for targeted gene silencing, which is nano-structured for targeted gene silencing, and a method for manufacturing the same.... Agent: Korea Advanced Institute Of Science And Technology

20130064788 - Il-17 family cytokine compositions and uses: Binding proteins, including non-naturally occurring and recombinantly modified proteins that bind to an IL-17R and including proteins having a mutated IL-17 cytokine sequence, methods of making such molecules and methods of using such molecules as therapeutic, prophylactic and diagnostic agents are provided.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20130064787 - Methods for treatment of hiv and other infections using a t cell or viral activator and anti-retroviral combination therapy: Disclosed is a method for treating infection with a pathogen. The method involves administration of: (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD4+ T cells from peripheral blood mononuclear cells isolated... Agent:

20130064789 - Hairy cell leukemia biomarkers and methods of using same: The present invention relates to hairy cell leukemia biomarkers and methods of utilizing these biomarkers to diagnose and/or treat hairy cell leukemia.... Agent:

20130064791 - Interferon analogs: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and... Agent: Biorion Technologies B.v.

20130064790 - Peptides with the capacity to bind to interleukin-10 (il-10): The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.... Agent: Proyecto De Biomedicina Cima, S.l.

20130064792 - Therapy for influenza like illness: An agent selected from: (a) interferon-β (IFN-β); (b) an agent that increases IFN-β expression; or (c) a polynucleotide which is capable of expressing (a) or (b); for use in the treatment of individuals with lower respiratory tract illness that has developed during or following an established ILI, wherein said treatment... Agent:

20130064793 - Compounds and pharmaceutical compositions for the treatment of viral infections: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.... Agent: Idenix Pharmaceuticals, Inc.

20130064794 - Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.... Agent: Idenix Pharmaceuticals, Inc.

20130064795 - Immune modulation: in which MI is Li+, MII is a divalent metal cation or a mixture of two or more divalent metal cations, MIII is a trivalent metal cation or a mixture of two or more trivalent metal cations, or a mixture of one or more trivalent metal cation with one or... Agent: Isis Innovation Ltd.

20130064796 - Methods for the prevention and control of pathogenic infections in bees and relative composition: The invention relates to a probiotic mixture for the protection of bees' health, and more specifically for the protection from microbial pathologies, such as those caused by Paenibacillus larvae, etiological agent of the American Foulbrood Disease (AFD).... Agent: Universita' Degli Studi Di Milano

20130064801 - Cellular compositions and methods of making and using them: The invention relates to cellular compositions comprising hematopoietic cells with the potential or increased potential to form non-hematopoietic cells; methods for producing such cellular compositions; methods for differentiation of cells of cellular compositions of the invention into cells that exhibit morphological, physiological, functional, and/or immunological features of non-hematopoietic cells; and... Agent: Mount Sinai Hospital

20130064797 - Composition for mucosally delivering fruit cell cultures and/or preparations derived therefrom and methods of using same: A pharmaceutical or nutraceutical composition comprising a cell line callus culture of grape berry cells grown in vitro, whereby the cell line callus culture of grape berry cells is derived from one or more of grape-berry cross section, grape-berry skin, grape-berry flesh, grape seed, grape embryo of seeded or seedless... Agent:

20130064798 - Methods and compositions for treating congestive heart failure: Compositions and methods for treating congestive heart failure are provided herein.... Agent: Theregen, Inc.

20130064799 - Methods for promoting cell reprogramming: The present invention is based on the seminal discovery that several kinases play important roles in barrier pathways in somatic cell reprogramming. The present invention provides that modulating expression or activity of these kinases can significantly promote or enhance cell reprogramming efficiency. Key kinases are identified and key regulation networks... Agent:

20130064800 - Tissue-engineered endothelial and epithelial implants differentially and synergistically regulate tissue repair: Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential... Agent: Massachusetts Institute Of Technology

20130064802 - Methods, compositions, and assays for determining the effect of an immune cell on a cell from an infectious or neoplastic disease: An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated CD8+ T-cell on a sensitized melanoma cell. A method for improving the specific... Agent:

20130064803 - Bio-replenishment (biorep) for cognitive health: Methods to prepare a bio-replenishment (BioRep) with specific combinations of S-adenosylmethionine (SAMe), lactoferrin (LF) and ribonuclease (RNAse) to restore cognitive health are disclosed. These methods have implications in the clinical management of cognitive afflictions such as anxiety, dementia and depression.... Agent: Naidu Lp

20130064804 - Bio-replenishment (biorep) for improving sleep architecture: Methods to prepare a bio-replenishment (BioRep) with specific combinations of S-adenosylmethionine (SAMe), lactoferrin (LF) and ribonuclease (RNAse) to restore regular sleep pattern are described. Additionally, compositions of functional delivery systems that recreate both alternate phases of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep cycles are disclosed. These... Agent: Naidu Lp

20130064805 - Highly functional enzyme having alpha-galactosidase activity: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein... Agent: Tokyo Metropolitan Organization For Medical Research

20130064806 - Novel pharmaceutical salts and polymorphs of a factor xa inhibitor: The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.... Agent: Millennium Pharmaceuticals, Inc.

20130064807 - Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors: The present disclosure provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or... Agent: Emory University

20130064808 - Biologically active oils: A process for the production of fats or oils and their extracts containing biologically active chemical compounds from a lipid substrate, the process comprising: a) inoculation of a lipid substrate with fungally derived lipolytic enzymes; b) incubating the inoculated substrate for a period of between about 7-120 days at a... Agent:

20130064809 - Antimicrobial composition and uses thereof: A composition for prophylactic and/or therapeutic medicinal applications, or plant protection applications, in particular for the control of microorganisms, either planktonic or organized in biofilms. The composition includes at least one ion selected from hypohalite, at least one compound selected from lactoferrin, lactoferrin peptide, lysozyme, immunoglobulins or a combination thereof,... Agent:

20130064810 - Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets: The present invention relates to microRNAs (miRNAs) which are associated with cancer, particularly including hematologic malignancies, and particularly T-cell acute lymphoblastic leukemia (T-ALL), and to the assessment and modulation thereof in the treatment and management of cancer. The present invention is directed to methods and compositions for diagnosing and treating... Agent:

20130064814 - Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells: The present disclosure provides methods and compositions for inhibiting the proliferation, differentiation, or development of stem cells and cancer stem cells in a patient in need thereof. The methods involve administering to a patient a therapeutically effective amount of an antagonist of an Hs.459642 Unigene Cluster product, such as an... Agent:

20130064812 - Combination therapies for hematologic malignancies: e

20130064817 - Engineered anti-il-23r antibodies: Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.... Agent: Merck Sharp & Dohme Corp.

20130064815 - Inducing apoptosis in quiescent cells: Compositions comprising an autophagy inhibitor and at least one of an NADPH modulator or a glutathione inhibitor are provided. Methods of inhibiting or killing a quiescent cell are provided. Methods of treating cancer are provided. Methods of identifying compositions that inhibit or kill quiescent cells are provided. Methods of identifying... Agent: The Trustees Of Princeton University

20130064811 - Methods to enhance cancer treatment: Herein are provided methods for reducing or eliminating cancer in a patient in need of cancer treatment, by providing cholesterol deprivation therapy (CDT) in conjunction with antibodies directed against cholesterol-deprived tumor cells. Further provided are methods of enhancing the efficacy of other cancer treatments, by administering CDT and antibodies directed... Agent: International Business Machines Corporation

20130064813 - Protein belonging to the tnf superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereof: A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting... Agent: The Rockefeller University

20130064816 - Tnf-alpha antagonists and methotrexate in the treatment of tnf-mediated disease: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.... Agent: The Mathilda And Terence Kennedy Institute Of Rheumatology Trust

20130064819 - Biomarkers: The use of HLA-DQA1 as a biomarker for predicting or determining the therapeutic efficacy of anti-TNF therapy.... Agent:

20130064818 - Use of immunesuppressant receptor: e

20130064820 - Methods and compositions for treating degos' disease: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and/or an inhibitor of interferon alpha, and the use of the compositions in methods for treating or preventing Degos' disease in a subject. In some embodiments, the inhibitor is an antibody, or antigen-binding fragment thereof, that... Agent: Alexion Pharmaceuticals, Inc

20130064821 - Methods and compositions for treating prostate cancer: A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased. Specifically disclosed is an AR IgG1 Fc fusion... Agent:

20130064823 - Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies: The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding do mains for two different binding sites of LRP6 and compositions and methods of use thereof.... Agent: Novartis Ag

20130064822 - Humanized anti-egfl7 antibodies and methods using same: The present invention concerns antibodies to EGFL7 and the uses of same.... Agent: Genentech, Inc.

20130064826 - Anti-emr1 antibodies: The invention provides anti-EMR1 antibodies and methods of using such antibodies to treat EMR1-related diseases.... Agent:

20130064829 - Antibodies specific for sclerostin and methods for increasing bone mineralization: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density... Agent: Ucb Manufacturing, Inc.

20130064830 - Antibodies specific for sclerostin and methods for increasing bone mineralization: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density... Agent: Ucb Manufacturing, Inc.

20130064828 - Chimeric vaccine for haemophilus influenzae-induced disease: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins... Agent: Nationwide Children's Hospital, Inc.

20130064824 - Combination pharmaceutical composition and methods of treating diabetes and metabolic disorders: The present application provides a pharmaceutical composition for administration to a patient suffering from diabetes and other metabolic disorders, the composition comprises a) an activated-potentiated form of an antibody to human insulin receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase.... Agent:

20130064827 - Il-17 homologous polypeptides and thereapeutic uses thereof: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide... Agent:

20130064825 - Methods of treating or preventing cholesterol related disorders: The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.... Agent: Amgen Inc.

20130064831 - Immunotherapeutic dosing regimens and combinations thereof: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of immunotherapeutic agents e.g. CTLA-4 antagonists such as Ipilimumab or Tremelimumab in combination with one or more chemotherapeutic agents in cancer patients.... Agent: Bristol-myers Squibb Company

20130064834 - Methods for treating hypercholesterolemia using antibodies to pcsk9: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.... Agent: Regeneron Pharmaceuticals, Inc.

20130064833 - Monitoring and modulating hgf/hgfr activity: Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis.... Agent: The General Hospital Corporation

20130064832 - Notch inhibition in the treatment and prevention of a metabolic disease or disorder and cardiovascular complications thereof: The present invention is directed to methods of treating or preventing a metabolic disease or disorder and cardiovascular complications and other complications thereof by administering agents that inhibit the NOTCH signaling pathway. In addition, the invention encompasses methods for determining whether a patient is at increased risk for developing these... Agent:

20130064836 - Compositions and methods for antibodies targeting complement protein c5: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.... Agent: Novartis Ag

20130064837 - Integrin alpha-v beta8 neutralizing antibody: The present invention relates to ανβ8 antagonists, anti-ανβ8 antibodies or immunoconjugates for reducing TGFβ activation in an individual. Further provided are compositions comprising one of the ανβ8 antagonists, anti-ανβ8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.... Agent: The Regents Of The University Of California

20130064835 - Rage regulates rock activity in cardiovascular disease: A method is provided for treating a RAGE-related disorder in a subject afflicted therewith comprising administering to the subject a therapeutically effective amount of an antagonist of rho-associated protein kinase 1 (ROCK1) so as to thereby treat the RAGE-related disorder. A method is also provided for treating a ROCK1-related disorder... Agent:

20130064838 - Enhanced death receptor agonists: Methods and compositions for treatment of cancer in a human patient comprising administering a therapeutically effective amount of an Fc-polypeptide agonist of DR5 having high-affinity to FCGR3A. Methods of making the Fc-polypeptides are provided.... Agent: Amgen Inc.

20130064839 - Method of rapidly producing improved vaccines for animals: A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or... Agent: Harrisvaccines, Inc.

20130064842 - Compositions and methods for detection of antibodies specific for anaplasma phagocytophilum (aph) and anaplasma platys (apl): The invention provides methods and compositions for the detection and treatment of Anaplasma phagocytophilum and Anaplasma platys infection.... Agent: Idexx Laboratories, Inc.

20130064840 - Hjurp peptides and vaccines including the same: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned... Agent: Onco Therapy Science ,inc

20130064841 - Immunogenic compositions against human progastrin peptides: Immunogens against human extended-progastrin species comprise (A) a mimetic peptide comprised of (i) the amino acid sequence of a progastrin or a N- and/or C-terminal processed species of a progastrin joined to (ii) a 7 amino-acid spacer coupled to (B) an immunogenic carrier. Illustrative of the mimetic peptide/spacer combination are... Agent: Onkologix Ltd

20130064843 - Identification of conserved peptide blocks in homologous polypeptides: Methods for identifying at least one conserved peptide block in three or more homologous polypeptides are provided and compositions comprising conserved peptides are provided. More particularly, methods for selecting conserved peptides in variable viral polypeptides for use in immunogenic compositions are provided.... Agent: Dana-farber Cancer Institute, Inc.

20130064844 - Non-splicing variants of gp350/220: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use... Agent: Medimmune, LLC

20130064845 - Bacterial vaccine components from staphylococcus aureus and uses thereof: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based... Agent: Socpra - Sciences Et Genie, S.e.c.

20130064846 - Neisserial antigens: The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.... Agent: Novartis Ag

20130064847 - Treatment and composition for achieving skin anti-aging benefits by corneum protease activation: Novel methods and compositions for treating aged and environmentally damaged skin are disclosed which provide improvements in the skin's visual appearance, function and clinical/biophysical properties by activating at least one proteolytic enzyme in the skin's stratum corneum. The disclosed treatment methods involve topical application of a novel cosmetic composition containing... Agent: Mary Kay, Inc.

20130064848 - Heterochain aliphatic poly-n-oxide copolymers and vaccinating agents and drugs based thereon: Heterochain aliphatic poly-N-oxide copolymers of general formula (1), where R═N, CH; x=2 or 4; y=0 or 2; n=10-1000; q=(0.1-0.9)n; z=(0.1-0.9)n, exhibit pharmacological activity, including an antioxidant effect and a therapeutic effect as a detoxicant and immunomodulating agent. The copolymer may be used as vaccinating agent also comprising an antigen and... Agent:

20130064849 - Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines: Embodiments of the invention include methods of treating or preventing cardiovascular disease, including atherosclerosis, myocardial infarction, and stroke, by administering an HPV vaccine, particular a vaccine that induces immunity against an oncogenic HPV type such as types 16 and 18.... Agent: The Board Of Regents Of The University Of Texas

20130064850 - Using modified plasmids to suppress antibiotic resistant pathogens: Methods of suppressing at least one species of micro-organism that is pathological to an organism. A first embodiment includes a method of suppressing at least one species of micro-organism that is pathological to an organism. A second embodiment includes a method of suppressing at least one species of micro-organism that... Agent:

20130064851 - Inactivated staphylococcal whole-cell vaccine: The vaccine that is protective against pathogenic bacterial species, typically staphylococcal species, and including methods to prepare said vaccine and to culture pathogenic bacteria.... Agent: Vaccine Research International PLC

20130064852 - Vaccine against mycoplasma, hyopneumoniae, suitable for administration in the presence of maternally derived antibodies: The invention pertains to a vaccine comprising Mycoplasma hyopneumoniae antigens for intradermal application to an animal that has maternally derived antibodies directed against Mycoplasma hyopneumoniae, to actively protect the animal against a disorder arising from an infection with Mycoplasma hyopneumoniae. The invention also pertains to the manufacture of this vaccine... Agent: Intervet International B.v.

20130064853 - Parasite vaccine: The present invention provides one or more antigens from the fourth stage (L4) larvae of non-blood feeding parasitic nematodes, for raising an immune responses in an animals, in particular bovines. The invention further provides methods of making immunogenic and/or vaccine compositions.... Agent:

20130064854 - Methods of treating allergies with substantially phenol-free carriers: A method for treating a patient suffering from allergy by desensitizing the patient to an allergen component that includes orally, sublingually, or intranasally administering to the patient a therapeutically effective amount of an immunomodulating composition and successively repeating the administration at a selected interval with the therapeutically effective amount of... Agent: Antigen Laboratories, Inc.

20130064857 - Methods and materials for making and using vaccines: This document relates to methods and materials for making and using vaccines. For example, vaccine preparations (e.g., whole cell vaccines and cell lysate vaccines) that can be used to treat cancer (e.g., human ovarian cancer) are provided.... Agent: Mayo Foundation For Medical Education And Research

20130064855 - Reprogramming immune environment in breast cancer via dendritic cells: Compositions and methods for the treatment of cancer disclosed herein. The method of the present invention comprises administration of compositions comprising β-glucan, a natural ligand for dectin-1, to block OX40L expression on tumor associated mDCs by blocking STAT6 phosphorylation. The β-glucan-treated mDCs secrete higher levels of IL-12p70 and do not... Agent: Baylor Research Institute

20130064856 - Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization: A universal vaccine containing a mixture of allogeneic cell lines, including tumor stem cells, effective against tumors regardless of type is disclosed. The cell lines are also modified to prevent interference with the immune response by any immunosuppressive agents they may secrete.... Agent: Novarx Corporation

20130064858 - Polysaccharide suitable to modulate immune response: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl... Agent: Unilever Nv

20130064859 - Combinatorial vitamin d and probiotic therapy for inflammatory bowel disease: A method of increasing the percentage of mouse and human Tregs is provided comprising providing B.fragilis or PSA and vitamin D or vitamin D metabolite to said mouse or human. Also, a method for treating inflammatory bowel diseases in an individual is presented where the individual is given a combination... Agent:

20130064860 - Combination pharmaceutical composition and methods of theating genitourinary system disorders: m

20130064868 - Composition for enhancing transdermal absorption of a drug and patch preparation: A composition for enhancing transdermal absorption of a drug, comprising an unsaturated higher alcohol having 12-20 carbon atoms and a polyvalent alcohol having 3-8 carbon atoms. A composition for enhancing transdermal absorption of a drug, comprising an unsaturated higher alcohol having 12-20 carbon atoms, a polyvalent alcohol having 3-8 carbon... Agent:

20130064869 - Composition for enhancing transdermal absorption of a drug and patch preparation: c

20130064861 - Compositions and methods for modifying in vivo calcification of hydrogels: Provided herein according to some embodiments of the invention are methods of inhibiting or preventing calcification of hydrogels. Such methods may include combining the hydrogel with a buffer solution having a pH lower than 7.4; forming a hydrogel by crosslinking alginate in a solution comprising a bisphosphonate compound; and/or forming... Agent:

20130064870 - Dry powder inhalation composition: o

20130064863 - Multicomponent and biocompatible nanocomposite materials, methods of synthesizing same and applications of same: One aspect of the present invention relates to a method of synthesizing a multicomponent and biocompatible nanocomposite material, which includes: synthesizing a gold/hydroxyapatite (Au/HA) catalyst; distributing the Au/HA catalyst into a thin film; and heating the thin film in a reactor with a carbon source gas to perform radio frequency... Agent: Board Of Trustees Of The University Of Arkansas

20130064867 - Nanoemulsion respiratory syncytial virus (rsv) subunit vaccine: The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (RSV) surface proteins, Fusion (F) and Glycoprotein (G) proteins subunit vaccine preferentially mixed with the immune cell targeting and enhancer, nanoemulsion to induce a protective immune response and avoid vaccine-induce disease enhancement.... Agent: Nanobio Corporation

20130064866 - Pulmonary and nasal delivery of serum amyloid p: The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.... Agent: Promedior, Inc.

20130064864 - Submicron particles to decrease transfusion: A submicron protein sphere and method to intravenously treat a patient requiring blood component transfusion. The submicron protein spheres have a size ranging from 1.0 micron to less than 0.1 micron and a molecular weight ranging from 780 billion Daltons to less than 0.8 billion Daltons. The protein spheres have... Agent:

20130064862 - Systems and methods for shell encapsulation: Certain aspects of the invention are generally directed to particles comprising a shell and an interior at least partially contained by the shell. In some embodiments, the particles may be treated to enhance the containment of the interior, for example to reduce transport of an agent into or out of... Agent: President And Fellows Of Harvard College

20130064865 - Therapy to reduce extravasation damage: A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The... Agent:

20130064871 - Composition comprising a dibenzoylmethane screening agent and a merocyanine dicyano or cyanoacetate derivative; method for the photostabilization of the dibenzoylmethane screening agent: The present invention relates to a cosmetic composition comprising the combination i) of at least one screening agent of the dibenzoylmethane derivative type and ii) of at least one specific merocyanine dicyano or cyanoacetate derivative. It also relates to a method for the photostabilization, with regard to radiation, of at... Agent: L'oreal

20130064872 - Skin preparation composition for external use with excellent antibacterial and antifungal effects: The present invention relates to a skin preparation composition for external use with an excellent antibacterial effect, and more specifically, to a skin preparation composition for external use with excellent antibacterial and antifungal effects against bacteria and mold, comprising a first composition containing citric acid as an active ingredient and... Agent:

20130064873 - Nucleated tablet for contact lens cleaning, contact lens cleaning preparation containing same, and method for cleaning contact lens: An object of the present invention is to provide a nucleated tablet for contact lens (CL) cleaning that makes it possible to disinfect a CL simply and easily in the presence of a foaming component; a CL cleaning preparation that contains the nucleated tablet; and a method for cleaning a... Agent: Ophtecs Corporation

20130064874 - Method for producing orally administrable edible agent of aggregated substance-containing laminate film form and orally administrable edible agent of aggregated substance-containing laminate film form: In pressure bonding edible layers having irregular surfaces due to the presence of aggregated substance so that the irregular surfaces face each other, an edible layer substantially free of any aggregated substance is interposed therebetween. This allows an orally administrable edible agent of aggregated substance-containing laminate film form having a... Agent: Kyukyu Pharmaceutical Co., Ltd.

20130064875 - Composition for enhancing transdermal absorption of a drug and patch preparation:

20130064877 - Composition for the transdermal delivery of fentanyl: A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery... Agent: 3m Innovative Properties Company

20130064876 - Process of treatment of fibers and/or textile materials: A process of treatment of textile materials containing microcapsules of active ingredients, the fibers and/or textile materials resulting from this process and their cosmetic or pharmaceutical use and/or their use as a repellent.... Agent: Lipotec S.a.

20130064878 - Wound healing compositions and methods: The invention provides a method of accelerating the healing process of a skin or subdermal wound. The method can include administering to a mammal afflicted with a skin or subdermal wound an effective amount of a gelatinase inhibitor, or a pharmaceutically acceptable salt thereof, wherein the gelatinase inhibitor is effective... Agent: University Of Notre Dame Du Lac

20130064880 - Administration regime for n-hydroxy-4-benzamide: or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days... Agent: Les Laboratoires Servier

20130064879 - Compositions and methods for inhibiting viral replication: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical... Agent:

20130064882 - Compositions and methods for the prevention of cancer in high risk patients: This relates to the prevention of cancer initiation. More specifically, the invention provides compositions and methods useful for altering the genetic signature in breast tissue, said alteration being correlated with a reduced risk for the development of breast cancer.... Agent: Fox Chase Cancer Center

20130064881 - Compositions and methods for treating prostate cancer: Compositions and methods to interfere with Androgen Receptor (AR) action based on bifunctional shRNA, targeting the AR and/or expression of SRC derived peptides are disclosed herein.... Agent: Gradalis, Inc.

20130064883 - Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof: A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and... Agent: Insmed Incorporated

20130064884 - Composition and method for treating ketosis in cows: A method for prophylactic treatment of ketosis in a calving cow, the method including orally administering to the cow within a time period of about 12 hours after calving an effective dose of from 20 to 30 g of rumen protected methionine. If the cow falls into a risk category,... Agent: Rp Feed Components, LLC

20130064885 - Probiotic products for pet applications: An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically Pediococcus acidilactici and Saccharomyces boulardii. Such encapsulation protects the viability of the probiotic microbes against unfavorable temperatures. An exemplary embodiment providing one or... Agent:

20130064886 - Microtablets for drug delivery: Methods and systems are provided for making a drug microtablet. The method includes loading a lyophilization capillary channel with a liquid drug solution; lyophilizing the liquid drug solution in the lyophilization capillary channel to produce a lyophilized drug formulation; compressing the lyophilized drug formulation in the lyophilization capillary channel, or... Agent: On Demand Therapeutics, Inc.

20130064887 - Pharmaceutical compositions: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.... Agent: Boehringer Ingelheim International Gmbh

20130064891 - Pharmaceutical compositions of nsaid and acid inhibitor: The present invention relates a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients, wherein non-steroidal anti-inflammatory drug is present in two or more portions. More particularly, the invention relates to compositions comprising Esomeprazole and Naproxen and a process for preparation thereof. Further... Agent:

20130064890 - Pharmaceutical formulation based on ibuprofen and codeine having improved stability: Pharmaceutical formulation based on ibuprofen and codeine having improved stability. The invention consists of a novel pharmaceutical formulation having the form of tablets or similar comprising a core composed of an association of ibuprofen and codeine as active ingredients, together with an excipient including at least a diluent, a disintegrating... Agent: Farmasierra Manufacturing, S.l.

20130064888 - Pharmaceutical formulations: The present invention provides a pharmaceutical dosage form in the form of a tablet comprising: (a) a compressed inert core, (b) an optional subcoat over the compressed inert core, (c) a drug layer over the compressed core (a) or optional subcoat (b) comprising a drug having a water solubility at... Agent:

20130064889 - Tablet-in-tablet palperidone formulations and methods for production and use thereof: Tablet-in tablet paliperidone formulations and processes for preparation and use thereof are provided.... Agent: Aptapharma, Inc.

20130064892 - Cellulosic gel material as a pharmaceutical excipient: A method of making a pharmaceutical tablet comprises (a) combining (i) an aqueous networked cellulose gel with (ii) filler and (iii) an active agent to form a mixture thereof; (b) casting the mixture to form a wet tablet; (c) drying the wet tablet to form a dry pharmaceutical tablet; and... Agent:

20130064893 - Stabilized pharmaceutical composition: The invention relates to stabilized pharmaceutical composition comprising pregabalin and a disaccharide or higher polyol as stabilizer and optionally a conventional pharmaceutically acceptable carrier. The stabilized pharmaceutical composition according to the invention is useful in the treatment of a number of diseases such as epilepsy, Alzheimer's disease or Parkinson's disease.... Agent:

20130064894 - Novel cationic lipids and methods of use thereof: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present... Agent: Protiva Biotherapeutics, Inc.

20130064895 - Amphiphilic peptides and peptide particles: The inventions provided herein relate to amphiphilic peptides and particles comprising the amphiphilic peptides. Such amphiphilic peptides and particles described herein can be used as a delivery system, e.g., for therapeutic or diagnostic purposes, or as cell penetration vehicles or cell transfection agents.... Agent: President And Fellows Of Harvard College

20130064896 - Gastroretentive solid oral dosage forms with swellable hydrophilic polymer: The disclosure provides multiparticulate systems that give release of active agents with a narrow window of absorption such that there is bioavailability to a patient. The disclosure provides a composition comprising microparticulates comprising a swellable hydrophilic polymer and an active agent, wherein the swellable hydrophilic polymer is substantially non-crosslinked intramolecularly,... Agent:

20130064897 - New process for producing hydrodispexible dry pharmaceutical composition and the pharmaceutical compositions thus obtained: The invention relates to life's necessities and in particular those relating to health, more particularly a method for dissolving and improving the intestinal absorption of active ingredients which are poorly-water-soluble or water-insoluble or which cannot be turned into salts in gastric juice, containing one or more active ingredients dispersed in... Agent:

20130064898 - Chinese medicine composition for treating cancer: A composition for treating tumors caused by pancreatic, stomach, breast, or liver cancer, leukemia, lung or liver metastasis, and/or arterial aneurysm. The composition comprises in various parts; turtle shell, radix ranunculi ternati, rhizoma dioscoreae bulbiferae, concha arcae, fructus ligustri lucidi, cordyceps sinensis, dwarf lilyturf tuber, Whim brownii, radix astragali, angelica... Agent:

20130064899 - Synergistic biocide composition containing at least three biocide components: The invention relates to a biocide composition which contains (A) silver, (B) one or more pyrithione(s) and (C) one or more 1,2-benzisothiazolin-3-one derivative(s) as microbiocidal active components.... Agent: Thor Gmbh

20130064900 - Anti-dandruff methods, processes and compositions: New methods, compositions, and processes for the treatment of symptoms of dandruff using cellular adhesion modulators are disclosed.... Agent:

20130064901 - Gene expression profiling for classifying and treating gastric cancer: The invention relates to methods for diagnosis and prognosis of gastric cancer. The approach described herein can distinguish intestinal-type gastric cancer (G-INT) from diffuse-type gastric cancer (G-DIF). The genomic expression signatures of G-INT and G-DIF define two major sets of genes. A diagnosis of gastric cancer G-INT and G-DIF can... Agent: Agency For Science, Technology And Research

20130064902 - Phosphaplatins and their use for treatment of cancers: Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and... Agent: Ohio University

20130064903 - Rheumatiod arthritis cure: A cause and cure for Rheumatiod Arthritis which includes the body becoming acid and retaining fluids as a means of diluting said acid. Calcium with adequate vitamin D for absorption neutralizes said acid and brings the body back in balance. In addition, an overabundance of the mineral potassium slows the... Agent:

20130064904 - Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof: The present invention features sulfur-rich compositions and preparations thereof that are safe and effective as hydrogen sulfide prodrugs of high bioavailability. The invention also includes methods of treating pathological conditions associated with oxidative stress using sulfur-rich compositions. The invention further includes sulfur-rich compositions as antidotes and medical food for preserving... Agent: Nuevas Alternativas Naturales, S.a.p.i. De C.v.

20130064907 - Combinations of antifungal compounds and tea tree oil: There is disclosed a method for treating a plant infection caused by a fungus of the class ascomycetes, comprising applying to the plant a combination of tea tree oil (TTO) and a synthetic fungicidal compound. Other embodiments are also disclosed.... Agent:

20130064906 - Herbal skin care composition: A topical skin care composition containing an extract solution of Dendrobium Huoshanense and a topical carrier.... Agent: Nefeli Corp.

20130064905 - Method for enhancing the growth and fullness of hair: New fibroblast growth factor receptor 1 (FGFR1) inhibitors have been identified which are useful for promoting the retention and/or growth of keratin fibers, such as hair of the scalp, hair of the face (moustache, beard, etc.), eyebrows, eyelashes, and the like. The FGFR1 inhibitors may be formulated in effective amounts... Agent: Avon Products, Inc.

20130064908 - Composition for preventing hair loss, with excellent hair styling function, and hair tonic containing same: An alopecia prevention composition consists of 0.1˜3 weight % of salicylic acid, 0.1˜5 weight % of tocopherol acetate, 0.1˜3 weight % of nicotinic acid amide, 0.1˜1 weight % of polyvinylpyrrolidone, 8˜12 weight % of ethanol, 0.3˜0.5 weight % of polyoxyethylene hydrogenerated castor oil, 0.2˜0.4 weight % of solid ginseng extract,... Agent:

20130064909 - Agglomerated oil impregnated psyllium husk: There is provided agglomerated oil impregnated psyllium husk and to a method for manufacturing the agglomerated oil impregnated psyllium husk. Specifically the present invention provides compositions comprising agglomerates of psyllium husks, wherein the husks have been subjected to treatment with an oily component (e.g. vegetable oil, such as rapeseed oil)... Agent: Biofiber-damimo A/s

20130064910 - Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria: e

20130064911 - Method and formulation for treating dry ear inflammation with cortisone: The present invention provides a method and formulation for treating and preventing asteatosis or “dry ear” symptoms and inflammation. The method of the present invention comprises topically applying to the ear canal a semi-viscous diglycerin and butylene glycol polyhydroxy liquid formulation including hydrocortisone, a natural product anti-irritant, a wound healing... Agent:

20130064912 - Formulation for alleviation of kidney stone and gallstone symptoms: A nutraceutical formula and food-based medicinal composition is provided comprising homeopathic ingredients in combination with traditional herbal and nutraceutical ingredients for relieving the symptoms associated with presence or formation of kidney stones and gallstones. The formulation includes ingredients balanced in a synergistic manner to elicit complementary effects which both reduce... Agent:

20130064913 - Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes: Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.... Agent: Metaproteomics, LLC

20130058863 - 4-protein biomarker panel for the diagnosis of lymphoma from biospecimen: A panel of lymphoma related biomarkers are provided. The panel allows the identification of a subject at risk for a lymphoma. Further provided are methods of optimizing therapeutic efficacy associated with treatment of a lymphoma related disorder. Methods of identifying biomarkers affiliated with a condition of interest are provided.... Agent:

20130058864 - Antibodies that bind ov064 and methods of use therefor: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding... Agent: Millennium Pharmaceuticals, Inc.

20130058865 - 99mtc-labeled 19 amino acid containing peptide for use as phosphatidylethanolamine binding molecular probe and radiopharmaceutical: The invention encompasses radiopharmaceutical compounds that can be used in imaging cell death associated with either apoptosis or necrosis. Phosphatidylethanolamine (PtdE) is externalized to the surface of apoptotic cells, and also becomes accessible in necrotic cells due to compromised plasma membrane integrity. Duramycin, a 19 amino acid polypeptide, binds PtdE... Agent:

20130058866 - N-pyrazole a2a receptor agonists: e

20130058867 - Solid composition for the oral administration of dyes and diagnostic use thereof: The present application discloses solid compositions for the oral administration of dyes, and diagnostic use thereof. Preferably, such diagnostic use is aimed at the diagnostic evaluation of the gastrointestinal tract.... Agent: Cosmo Technologies Ltd.

20130058868 - Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo: The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of... Agent: Bundesrepublik Deutschland Letztvertreten Durch Das Robert- Koch-lnstitut Vertreten Durch Seinen

20130058870 - 3d nanocrystals and manufacturing methods: The invention relates to nanocrystals, containing one or more metals as defined in the specification; having a size of 2 to 200 nm; having a defined, three-dimensional polyhedral structure, optionally functionalized by ligands and/or embedded crystals. The invention further relates to monodisperse assemblies of such nanocrystals, to formulations and devices... Agent: Eth Zurich

20130058869 - Prevention and treatment of amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease.... Agent: Janssen Alzheimer Immunotherapy

20130058874 - Chemical exchange saturation transfer based mri using reporter genes and mri methods related thereto: Featured are a new class of reporter genes including reporter compositions as well as methods, MRI systems and MRI imaging kits related thereto. The genes according to the present invention provide MR contrast when the sample/subject is irradiated at a specific off-resonance radio-frequency (RF frequency), where the contrast mechanism utilizes... Agent: The Johns Hopkins University

20130058873 - P97 fragments with transfer activity: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.... Agent: Bioasis Technologies, Inc.

20130058872 - Bioluminescent endoscopy methods and compounds: Bioluminescent endoscopy methods in which bioluminescent generating system components are combined ex vivo immediately prior to injection or infusion into a tissue area of interest to enable bioluminescent viewing of the tissue. The bioluminescent generating system components are combined by simultaneous injection into a Y tube or other in-line mixing... Agent:

20130058871 - Method and system for mapping synaptic connectivity using light microscopy: A mammalian Green Fluorescent Protein (GFP) Reconstruction Across Synaptic Partners (mGRASP) method and system is provided by optimizing synaptic transmelectron microscopicbrane carriers for mammalian synapses. The method and system in one form integrates molecular and cellular approaches with a novel computational strategy to reliably reconstruct neurons in 3D. The method... Agent: Howard Hughes Medical Institute

20130058875 - Capsule having broad color spectrum: The present invention is directed to a capsule comprising a water-soluble compound suitable for the capsule, a non-water soluble excipient suitable for the capsule; and suitable for the capsule, and a mixture of colorant agents, wherein the color of the capsule may be in the range of 15<L<90; −30<a<+75; −37<b<+46... Agent:

20130058876 - (trimethoxyphenylamino) pyrimidinyl formulations: There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and... Agent: Astrazeneca Ab

20130058877 - Calculus dissolution compositions and methods for using same: The present invention relates generally to an anti-calculus composition and method for treating subgingival calculus. The anti-calculus composition comprises a pyrophosphate and a tripolyphosphate in a pharmaceutically acceptable carrier. The composition may also comprise a fluoride providing compound.... Agent:

20130058878 - Cosmetic use of geranylgeranyl-2-propanol: Geranylgeranyl-2-propanol compound (GGP) having the following formula (I) is proposed for use according to the present invention as a cosmetic active compound for the prevention and treatment of aging of skin and its appendages. The GGP has a protective action against oxidative stress and free radical, on telomeres and on... Agent: Sederma

20130058879 - Triazines as reaction accelerators: The invention relates to the use of at least one specific triazine or melamine and/or salt thereof as accelerator for a photoinduced reaction of 3-(4-tert-butylphenyl)-3-hydroxy-1-(4-methoxyphenyl)-propan-1-one, 1-(4-tert-butylphenyl)-3-hydroxy-3-(4-methoxyphenyl)-propan-1-one or a mixture of these compounds to give avobenzone. The invention furthermore relates to a composition comprising at least one specific triazine or melamine... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20130058880 - Film forming personal care compositions and methods: Compositions, kits and methods of preparing a biocompatible film for cosmetic or medical uses are disclosed. The compositions or kits contain polyvinyl acetal (PVA), siloxane and a solvent. The siloxane can have a hydrophilic group. Once the solvent content is reduced, for instance, by evaporation, the mixture of PVA and... Agent:

20130058881 - Organic compounds: Deodorant composition for the treatment of female malodour comprising a perfume containing violet nitrile and optionally pharaone and/or zinarine.... Agent: Givaudan Sa

20130058882 - Personal care composition comprising butylated hydroxyanisole compound: A personal care composition which has an ethylenic monomer having a molecular weight of 500 g/mole or less and a compound selected from the group consisting of 2-tert-butyl-4-hydroxy-anisole, 3-tert-butyl-4-hydroxy-anisole, and mixtures thereof. The compound is present in the personal care composition in an amount of from about 1 milligram to... Agent:

20130058883 - Composition for making up and/or caring for keratinous fibers and presenting improved staying-power properties: A cosmetic composition for making up and/or caring for keratinous fibers. The composition includes at least: an oily phase formed at least of isododecane, and at least 4% by weight, relative to the total weight of the composition, of at least one oil of volatility that is less than that... Agent: L'oreal

20130058884 - Herbal oil which is used in hair care and in massage and which is used in treatment of hair loss, hairlessness, and burns: A compound which is obtained by mixing olive oil with natural vegetables and their essentials which are used in hair care and which prevents hair loss, removes deformation and allows healthy hairs to regrow if hair has been lost, allows new hairs coming out when it is applied where hairlessness... Agent:

20130058885 - Personal care compositions comprising squash or pumpkin extract: Embodiments of the present invention relate to novel personal care compositions for cleaning and moisturizing the skin or hair comprising an extract of squash and/or pumpkin, a preservative and a cosmetic base. Other embodiments of the present invention relate to methods of making and methods of using the personal care... Agent: Burt's Farm, LLC

20130058887 - Aldehyde-removing composition: An object of the present invention is to provide a composition for removing aldehyde. Specifically, the present invention relates to an aldehyde-removing composition comprising a microorganism belonging to the genus Gluconobacter having aldehyde-degrading activity, or extracts thereof or disrupted cells thereof, wherein the microorganism belonging to the genus Gluconobacter has... Agent: Tohoku University

20130058886 - Perfume compositions comprising functional perfume components: Perfume compositions having functional perfume components for aiding in perfume evaporation. The functional perfume components have a Kovat's index in the range of 900-1400 and an ODT of greater than about 1 ppb. In one embodiment, the functional perfume component may be present in an amount from at least about... Agent: The Procter & Gamble Company

20130058888 - Compositions comprising soil adsorption polymers for reducing particulates in the air: Compositions comprising soil adsorption polymers for reducing particulates in the air are provided.... Agent:

20130058889 - Antifouling paint composition, production method of antifouling paint film, and antifouling paint film: The present invention provides an antifouling paint composition, by which a paint film can be formed using a small amount of an organic solvent, in which the strength and the self-abradability can be maintained for a long period, and by which a paint film having an excellent antifouling property can... Agent: Mitsubishi Rayon Co., Ltd.

20130058890 - Methods for controlling pests using rnai: The present invention concerns methods for controlling insect infestation via RNAi-mediated gene silencing, whereby the intact insect cell(s) are contacted with a double-stranded RNA from outside the insect cell(s) and whereby the double-stranded RNA is taken up by the intact insect cell(s). In one particular embodiment, the methods of the... Agent: Devgen Nv

20130058891 - Kexin-derived vaccines to prevent or treat fungal infections: A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having... Agent:

20130058892 - Pyrimidinyl indole compounds: The present invention provides pyrimidinyl indole compounds as novel kinase inhibitors for the treatment of cancer and inflammatory diseases.... Agent: Hutchison Medipharma Limited

20130058893 - Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active... Agent:

20130058894 - Therapeutic protein-specific induced tolerogenic dendritic cells and methods of use: Disclosed are therapeutic protein-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods.... Agent: Selecta Biosciences, Inc.

20130058895 - High pressure treatment of aggregated interferons: Methods are provided using high pressure to treat aggregated interferons, to reduce the aggregate content of interferon material. In particular, recombinant human interferon-β may be so treated. Multiple strategies may be used in combination to make nonglycosylated IFN-β more amenable to high pressure treatment. When coupled with purification techniques, these... Agent: Nuron Biotech, Inc.

20130058896 - Compositions and methods related to anti-fgf agents: The invention relates to an isolated amino acid that can act as an antagonist to FGF signaling, comprising at least a portion of the FGF protein amino acid sequence, and including a mutation in either a) the integrin αvβ3 binding region of FGF-1; or b) the FGFR binding region of... Agent: The Regents Of The University Of California

20130058897 - Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same: Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.... Agent: Mogam Biotechnology Research Institute

20130058908 - High affinity ny-eso t cell receptors: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or... Agent:

20130058898 - Lactic acid bacterium-containing preparation: The present invention provides very safe lactic acid bacteria and lactic acid bacteria preparations which are effective in prevention and therapy of allergies and/or in lowering of the blood neutral fat level. The present invention also provides pharmaceutical products and food or drink products which contain, as an active ingredient,... Agent: Kaneka Corporation

20130058899 - Cancer therapy with a parvovirus combined with an hdac inhibitor: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.... Agent: Deutsches Krebsforschungszentrum

20130058905 - Angiohematopoietic progenitor cells: A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a.... Agent:

20130058902 - Dendritic cell subsets for generating induced tolerogenic dendritic cells and related compositions and methods: Disclosed are induced tolerogenic dendritic cells (itDCs) produced from dendritic cell subsets that possess a desired physiological characteristic, as well as related compositions and methods.... Agent: Selecta Biosciences, Inc.

20130058907 - Method and system for the production of cells and cell products and applications thereof: A cell culture system for the production of cells and cell derived products includes a reusable instrumentation base device incorporating hardware to support cell culture growth. A disposable cultureware module including a cell growth chamber is removably attachable to the instrumentation base device. The base device includes microprocessor control and... Agent: Biovest International, Inc.

20130058904 - Method and system for treatment of biological tissue: A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative.... Agent: Francis Law Group

20130058900 - Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells: The invention is concerned with producing differentiated cells, tissues and organs from pluripotent and mutlipotent cells. The methods of the invention are particularly useful for producing differentiated cells from pluripotent cells wherein communication between the cells of more than one embryonic germ layer or more than one organ system are... Agent:

20130058906 - Process, tube and device for the preparation of wound healant composition: The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.... Agent:

20130058903 - Stem-cell material and method of use: Provided herein are mesenchymal stem cells which have been modified by the introduction of polynucleotides encoding for a mammalian Cdk1 protein. These cells do not sense in culture and are non-tumorigenic thereby providing an ongoing source of cells as well as conditioned medium. The conditioned medium from these cells can... Agent:

20130058901 - Transplantable graft-specific induced tolerogenic dendritic cells and methods of use: Disclosed are transplantable graft-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods.... Agent: Selecta Biosciences, Inc.

20130058909 - Methods of treatment using ex vivo expansion of cord blood t cells: Provided are methods of enhancing ex vivo proliferation of a T cell population, the methods comprising contacting the T cell population with IL-7 and anti-CD3/CD28 antibody to activate and expand the T cell population. Further provided are methods of generating an antigen-specific cytotoxic T cell population comprising priming a CD3/CD28-expanded... Agent: Duke University

20130058910 - Decontamination of chemical and biological agents: A system includes at least one oxidase. at least one haloperoxidase; at least a first polymer including groups exhibiting nucleophilic activity for organophosphorus compounds, and a source of halide ions to serve as a substrate for haloperoxidase-catalyzed generation of halogens. The source of halide ions may, for example, include salt... Agent:

20130058911 - Reducing agent from microorganism belonging to genus bacillus and application for same: The present invention is intended to provide a reducing agent effective for color development of meat and uses therefor. The present invention provides a reducing agent containing a heme reductase derived from a microorganism belonging to the genus Bacillus. Preferably, crushed bacterial cells of Bacillus subtilis, Bacillus amyloliquefaciens, Bacillus natto,... Agent: Amano Enzyme Inc.

20130058913 - Lactase formulations: A particulate composition comprising a plurality of particles comprising lactase and a protective material are provided. The particles have a size that is not perceptible or is minimally perceptible on the human tongue. The particulate composition can be made by a method that comprises the steps of providing a lactase,... Agent:

20130058912 - Therapeutic charge engineered variants of lysozyme and methods for using same to treat infections: The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrobial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly... Agent:

20130058917 - Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column: The invention relates to populations of antibodies obtainable by fractionation of plasma immunoglobulins, in particular plasma IgG, by affinity chromatography on a Sambucus nigra affinity column, and uses thereof.... Agent:

20130058914 - Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof: The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid... Agent: Celera Corporation

20130058918 - Isolation and use of a new type of glial cell with neurotoxic potential: The present invention provides for an isolated population of aberrant astrocytes, methods of isolating the aberrant astrocytes, methods of diagnosing neurodegenerative diseases, methods of drug screening using the aberrant astrocytes, and treatment methods targeting function, activity, and signaling associated with aberrant astrocytes.... Agent: Cedars-sinai Medical Center

20130058915 - Methods and compositions for treatment of angelman syndrome and autism spectrum disorders: Methods for the treatment of Angelman Syndrome autism spectrum disorders are provided. The methods comprise administrating to a subject an agent that increases the expression of or increases activity of, ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) at neuronal synapses.... Agent: President And Fellows Of Harvard College

20130058916 - Proangiogenic compositions, method for preparing same, and uses thereof: The disclosure relates to an electrodynamic-transducer magnetic motor device (10) having a moving coil comprising a magnetic circuit consisting of a tied angular magnet (11), characterized in that said tied annular magnet has a hollow annular structure, said hollow annular structure comprising an annular cavity (12) connected to an upper... Agent:

20130058927 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent: Genentech, Inc.

20130058923 - Biomolecular interactions and interaction products as biomarkers for detection, diagnosis, prognosis and predicting therapeutic responses of human diseases: Included in the disclosure is description of a method of determining a presence, and/or aggressiveness level, and/or response to therapy of a human disease in a subject. The method involves determining size of nanoparticles upon being exposed to a biological sample or a component of biological sample or pretreated biological... Agent:

20130058925 - Epithelial biomarkers for cancer prognosis: Methods, systems and compositions for the prognosis and classification of cancer, especially bladder cancer, are provided. For example, in certain aspects methods for cancer prognosis using expression analysis of selected biomarkers such as miR-200 and TGFalpha are described.... Agent: Board Of Regents, The University Of Texas System

20130058924 - Hypoxia-related gene signatures for cancer classification: Biomarkers, particularly hypoxia-related genes, and methods using the biomarkers for molecular detection and classification of disease are provided.... Agent: Myriad Genetics, Incorporated

20130058926 - Method for alleviating and/or preventing skin reddening: A method of alleviating and/or preventing skin reddening for a subject in need thereof by means of inhibiting angiogenesis at the site of the reddened skin, is provided.... Agent: Shiseido Company, Ltd.

20130058920 - Methods for improving the bioactivity of therapeutic ige antibodies for the treatment of disease: The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent,... Agent: Advanced Immune Therapeutics, Inc.

20130058919 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Xencor, Inc.

20130058922 - Pharmaceutical composition containing choline: The invention further relates to pharmaceutical compositions, in particular for intravenous administration, containing choline or pharmaceutically acceptable salts or analogues thereof, alone or in combination with vitamin C and/or L-arginine and/or vitamin D3 (cholecalciferol) for use in the fight against CTCs, DTCs or dysfunctional leukocyte precursors in the blood or... Agent:

20130058921 - Use of autologous effector cells and antibodies for treatment of multiple myeloma: The present disclosure provides methods for treating multiple myeloma using a combination of autologous expanded and activated NK cells from the patient and an antibody that targets an antigen on myeloma cells and/or an antibody that targets the KIR antigen on NK cells, wherein the antibodies elicit ADCC toward myeloma... Agent:

20130058929 - Fusion proteins for inhibition and dissolution of coagulation of thrombi: Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising... Agent: The Trustees Of The University Of Pennsylvania

20130058928 - Hair growth methods using fgfr3 extracellular domins: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.... Agent: Five Prime Therapeutics, Inc.

20130058931 - Methods of predicting and decreasing the risk of pregnancy loss: Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the... Agent: University Of Louisville Research Foundation, Inc.

20130058930 - Subcutaneous needle assisted jet injection administration of methotrexate: The present application is directed, at least in part, to a method of treating an autoimmune disorder in a subject in need of treatment. In one exemplary embodiment, the method comprises introducing into the subcutaneous tissue of the subject, from a needle assisted jet injection device, a composition comprising methotrexate... Agent: Antares Pharma, Inc.

20130058932 - Use of pkc-iota inhibitors for the treatment of glioma: The present invention pertains to use of PKC-iota inhibitors for treatment of glioma. In a specific embodiment, the treatment method comprises administering ICA-1 or a salt thereof to a subject with glioma. In another embodiment, the treatment method comprises contacting glioma cells with an effective amount of ICA-1 or a... Agent: University Of South Florida

20130058935 - Antibodies to tumor endothelial marker 7r: Antibodies that specifically bind to an epitope on the extracellular domain of TEM7R are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided. The antibodies may be used in methods for treating tumors and for inhibiting angiogenesis in tumors.... Agent: Fox Chase Cancer Center

20130058934 - Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies: The present disclosure relates to antibodies targeting LRP6 and compositions and methods of use thereof.... Agent: Novartis Ag

20130058933 - Monovalent ligands of the human cd28 receptor: The invention relates to monovalent ligands of the human CD28 receptor, which can selectively block the interaction between CD28 and B7 without activating the CD28 receptor. Said ligands can be used in particular in the production of immunosuppressant drugs, selectively blocking T lymphocyte activation phenomena involving the CD28 receptor.... Agent: Effimune

20130058936 - Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use: The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein... Agent:

20130058937 - Bispecific antigen binding molecules: The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and... Agent:

20130058938 - Gna11 mutations in melanoma: The present invention provides methods of detecting mutations in a GNA11 gene in a melanocytic neoplasm for diagnostic and prognostic purposes. The invention further provides methods of treating such melanocytic neoplasm by modulating the activity of the mutated GNA11 gene.... Agent: The University Of British Columbia

20130058944 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent: Amgen Inc.

20130058945 - Antigenic gm-csf peptides and antibodies to gm-csf: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the... Agent:

20130058943 - Bovine polyclonal antibody specific for human tnf: The invention provides a composition comprising polyclonal antibodies that specifically bind to with human tumor necrosis factor (hTNF) wherein the polyclonal antibodies are derived from the serum, milk or colostrum of a bovine animal that has been immunized hTNF or an immunogenic portion thereof. The antigenic specificity analysis of the... Agent:

20130058942 - Human beta-adrenergic receptor kinase polypeptide and methods: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.... Agent: Incyte Corporation

20130058941 - Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases: Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, the therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions.... Agent: Universitaet Basel

20130058940 - Novel gene and protein associated with angiogenesis and endothelial cell specific apoptosis: This invention provides isolated nucleic acid and amino acid sequences encoding VG5Q, a novel angiogenic growth factor protein with pro-angiogenic activity, a forkhead-associated domain, a G-patch domain; characteristic subcellular localization in an in vitro Matrigel model of angiogenesis: towards the cell periphery in early stages of tubulogenesis, between cells in... Agent: The Cleveland Clinic Foundation

20130058939 - Treatment of neurological or neurodegenerative disorders: The invention relates to a protein or peptide consisting of a kringle protein or peptide and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates also to an isolated antibody of fragment thereof which binds to the N-terminal domain of the NMDA receptor... Agent: Paion Deutschland Gmbh

20130058946 - Seizure and migraine treatments using denosumab: e

20130058947 - Novel modulators and methods of use: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.... Agent: Stem Centrx, Inc

20130058948 - Antibodies directed to gpnmb and uses thereof: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are... Agent:

20130058949 - Antagonists of il-6 to prevent or treat thrombosis: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other cogulation... Agent:

20130058951 - Anti-s1p antibody treatment of patients with ocular disease: The present invention relates to methods that involve administration of an anti-S1 P antibody or antibody fragment or derivative to a subject having or suspected of having an ocular disease or condition, including one involving choroidal neovascularization, in order to achieve a desired effect. Such effects include reducing the size... Agent: Lpath, Inc.

20130058950 - Methods for detecting progenitor cells and uses thereof: Diagnostic and therapeutic methods pertaining to diseases and disorders of the breast, uterus and ovary are encompassed herein. More particularly, diagnostic methods for early detection of progenitor cells of breast, uterine, and ovarian cancers are described herein. The identification of markers for these cancer predisposing progenitor cells, which co-express the... Agent:

20130058952 - Anti-hsv antibody: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable... Agent:

20130058953 - Characterization of the cbir1 antigenic response for diagnosis and treatment of crohn's disease: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and... Agent: Cedars-sinai Medical Center

20130058955 - Anti-polyubiquitin antibodies and methods of use: The invention provides anti-polyubiquitin antibodies and methods of using the same.... Agent: Genentech, Inc.

20130058958 - Compositions and methods useful for reducing the viscosity of protein-containing formulations: The invention relates to use of certain compounds including, for example, certain charged amino acids and structural analogs thereof, for reducing the viscosity of aqueous protein-containing formulations. Associated compositions of matter and methods of use are also contemplated within the present invention.... Agent: Genentech, Inc.

20130058957 - Dendritic cell immunoreceptor agonist: e

20130058954 - Diagnostic and therapeutic methods for corneal ectasia following refractive surgery, keratoconus or pellucid degeneration: The present invention relates to methods of diagnosis and treatment of corneal ectasia following refractive surgery, keratoconus or pellucid marginal degeneration in a subject by determining or modulating the level of expression of molecules associated with the Wnt signalling pathway. Marker molecules of the present invention include SFRP1, PITX2, LEF1,... Agent: The University Of Sydney

20130058956 - Extracellular ifi16 as therapeutic agents: The present invention relates to the inhibition of the circulating extracellular form of the interferon inducible protein 16 (extracellular IFI16) for the treatment of diseases, particularly autoimmune and/or inflammatory disorders or infective disorders.... Agent: Universita Degli Studi Del Piemonte Orientale "a Avogedro" (university Of Piemonte Orientale)

20130058959 - Hematopoietic cell selectin ligand polypeptides and methods of use thereof: The invention feature methods and compositions for treating inflammatory disorders, hematopoietic disorders and non-hematopoietic disorders (e.g., non-hematopoietic cancers) and for isolating cells (e.g., stem cells) in a mammal.... Agent:

20130058960 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20130058961 - Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition: The present invention provides methods for reducing the amidolytic and anti-complement activity (ACA) content of an immunoglobulin composition through the use of cation exchange chromatography. In a specific embodiment, the invention provides methods for reducing the Factor XI and/or Factor XIa and/or ACA content of an immunoglobulin composition by collecting... Agent: Baxter International Inc.

20130058962 - Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein: Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant heteromultimeric neutralizing binding protein including two or multiple binding regions, such that the binding regions are not identical, and each... Agent: Tufts University

20130058963 - Induced tolerogenic dendritic cells for generating cd8+ regulatory t cells: Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that generate CD8+ regulatory T cells, as well as related compositions and methods.... Agent: Selecta Biosciences, Inc.

20130058964 - Methods for activating t cells and modulating an immune response: The present invention is directed to a method for promoting differentiation, activation and proliferation of human T helper lymphocytes such as those that express IL17 and IL22 (Th-IL17+ and Th-IL22+ T cells) and provides methods for decreasing T cell activation or T cell biological activity, inhibiting an immune response and... Agent:

20130058966 - Anti-pdef antibodies and uses thereof: The present invention relates to an isolated antibody or antigen-binding fragment thereof that specifically binds with high affinity to at least a portion of a segment of human prostate-derived Ets transcription factor (PDEF). The anti-PDEF antibody of the present invention is effective in prognostic and diagnostic assays for detecting PDEF... Agent:

20130058965 - Injectable formulations for parenteral administration: Disclosed herein are uses, methods, and processes for preparing or manufacturing a lyophilized cake that comprises a water-insoluble agent, wherein the cake is capable of being disintegrated in a parenterally acceptable solvent to form a syringeable liquid suspension of fine particles of the water-insoluble active agent that is suitable for... Agent: Mannkind Corporation

20130058967 - Recombinant modified bacillus anthracis protective antigen for use in vaccines: The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an... Agent: The Government Of The United States Of America As Represented By The Secretary Of The Department Of

20130058969 - Chloroplasts engineered to express pharmaceutical proteins: Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts,... Agent:

20130058968 - Piscine reovirus immunogenic compositions: The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus poplypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an... Agent:

20130058970 - Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines: Disclosed are induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods, for reducing systemic inflammatory cytokines.... Agent: Selecta Biosciences, Inc.

20130058971 - Innoculation of recombinant viral vectors for rapid pre-exposure prevention and post-exposure protection against alphavirus-induced encephalitides: This invention addresses how to rapidly prevent alphavirus-induced encephalitides before and after exposure to alphaviruses. The invention discloses a single dose administration of two types of recombinant viral vectors: one expressing interferon and another expressing the structural proteins of alphaviruses or a single dose administration of the recombinant viral vector... Agent: Her Majesty The Queen, In Right Of Canada, As Represented By The Minister Of National Defence

20130058972 - Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof: The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of... Agent: Eastern Virginia Medical School

20130058973 - Immune therapy: Native Tat, when administered to patients with HIV infection, or who are otherwise immunocompromised, is capable of restoring immune functions so as to recognise recall antigens, and to inhibit replication and key signs of HIV disease and other persistent infections and/or their progression.... Agent: Vaxxit Srl

20130058976 - Allergen-specific induced tolerogenic dendritic cells for allergy therapy: Disclosed are allergen-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods.... Agent: Selecta Biosciences, Inc.

20130058975 - Antigen-specific induced tolerogenic dendritic cells to reduce antibody responses: Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing undesired humoral immune responses, as well as related compositions and methods.... Agent: Selecta Biosciences, Inc.

20130058974 - Antigen-specific induced tolerogenic dendritic cells to reduce cytotoxic t lymphocyte responses: Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing CD8+ T cell immune responses, as well as related compositions and methods.... Agent: Selecta Biosciences, Inc.

20130058977 - Compositions and methods related to induced tolerogenic dendritic cells externally loaded with mhc class i-restricted epitopes: Disclosed are induced tolerogenic dendritic cells (itDCs) produced by combining itDCs with externally loadable MHC Class I-restricted epitopes, as well as related compositions and methods.... Agent: Selecta Biosciences, Inc.

20130058978 - Induced tolerogenic dendritic cells for inducing regulatory b cells: Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that generate regulatory B cells, as well as related compositions and methods.... Agent: Selecta Biosciences, Inc.

20130058979 - Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination: We provide for the use of an intracellular antibody therapy for targeting intracellular oncoproteins or proteins to prevent cancer metastasis. We also provide for the use of an intracellular vaccine therapy comprising an oncoprotein protein for vaccination to stimulate a host to produce its own antibodies to prevent tumor formation.... Agent: Agency For Science, Technology And Research

20130058980 - Small molecule inhibitors of protein kinases: Compounds that modulate, for example, that inhibit, syk kinase, and, optionally other kinases. The compounds can be used to treat a variety of disorders, including inflammatory disorders and autoimmune disorders.... Agent:

20130058983 - Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT... Agent:

20130058981 - Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia: The present invention relates to combination pharmaceutical compositions comprising an activated-potentiated form of an antibody to endothelial NO synthase and activated potentiated form of an antibody to brain-specific protein S-100 and its use for the treatment of vegetative-vascular dystonia (VVD) and symptoms thereof.... Agent:

20130058987 - Enhanced folic acid fluorescent material, multifluorescent porous compositions of matter and potential applications thereof: A method for the preparation of enhanced fluorescent folic acid mesoporous material, multifluorescent mesoporous materials, their novel properties and applications such as: a mesoporous fluorescent composition suitable for printing identification marks on metals, glass, plastic, ceramics, or paper which are visible only when excited by an external radiation; and applications... Agent: Nanologica Ab

20130058988 - Metal cations and metal effect pigments comprising anions containing phosphorus and/or sulphur, method for producing said metal effect pigments and use thereof: m

20130058982 - Method of treating alzheimer's disease: The present invention relates to a method of treating Alzheimer's disease by administration of activated-potentiated form of antibodies to brain-specific protein S-100 and activated-potentiated form of antibodies to endothelial NO synthase.... Agent:

20130058984 - Single-walled carbon nanotube/bioactive substance complexes and methods related thereto: The present invention includes single-walled carbon nanotube compositions for the delivery of siRNA and methods of making such single-walled carbon nanotube compositions. A single-walled carbon nanotube composition for delivery of siRNA includes a nonfunctionalized single-walled carbon nanotube; and siRNA noncovalently complexed with the nonfunctionalized single-walled carbon nanotube, wherein the siRNA... Agent: William Marsh Rice University

20130058986 - Solid dosage forms comprising an enteric coating with accelerated drug release: The present invention provides a solid dosage form including an inner coating located between a core containing a pharmaceutically active ingredient and an outer enteric coating; wherein the inner coating includes a partially neutralized anionic polymeric material and at least a carboxylic acid having 2 to 16 carbon atoms, the... Agent: Evonik Roehm Gmbh

20130058985 - Spray-pumpable composition suitable for topical skin application: The present invention relates to a spray-pumpable composition for topical use on the skin comprising hydrophilic silicon dioxide, an emulsifier, at least one active ingredient and optionally one or more additives. The present invention further relates to a method for the preparation of a spray-pumpable composition for topical use on... Agent:

20130058989 - Capsule having broad color spectrum: The present invention is directed to a capsule comprising a water-soluble compound suitable for the capsule, and a mixture of colorant agents, wherein the color of the capsule may be in the range of 15<L<90; −30<a<+75; −37<b<+46 as measured in accordance with the Lab color space. The present invention further... Agent:

20130058990 - Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent: in which at least one or two of the radicals contain: either an alkylsulfonate radical in its acid or salified form, or one or two hydroxyl radicals. The invention also relates to a process for the radiation-photostabilization of at least one screening agent of the dibenzoylmethane derivative type with an... Agent: L'oreal

20130058991 - Matricryptic ecm peptides for tissue reconstruction: Chemoattractant polypeptide compounds for progenitor cells and compositions and drug products comprising the compounds are provided herein. Methods for attracting progenitor cells to a location in or on a patient also are provided along with methods of growing and repairing bone.... Agent: University Of Pittsburgh-of The Commonwealth System Of Higher Education

20130058995 - Composition and method for weight reduction: Disclosed is a composition and method for facilitating weight loss in individuals. The composition is a physiologically effective amount of the herbal substance Bauhinia in a suitable carrier. The carrier can be water, alcohol, mixtures thereof, capsules powders, tinctures, liposomes, chewing gum, lozenges, candies, food, skin creams, or lotions. The... Agent:

20130058998 - Encapsulated n-acetylmannosamine or n-acetylneuraminic acid to increase sialylation: A method for treating a disorder characterized by hyposialylation in a subject that includes administering to the subject an effective amount of (i) a composition comprising N-acetylmannosamine, or a derivative thereof, encapsulated within a liposome, or (ii) a composition comprising N-acetylneuraminic acid, or a derivative thereof, encapsulated within a liposome,... Agent: United States Of America As Represented By The Secretary, Department Of Health And Human Services

20130058992 - Gene expression signatures associated with response to imatinib mesylate in gastrointestinal stromal tumors and use thereof for predicting patient response to therapy and identification of agents which have efficacy for the treatment of cancer: Compositions and methods are disclosed for identifying agents useful for the treatment of malignancy, particularly GISTs which are resistant to imatinib mesylate (IM). In a preferred embodiment, agents which sensitize cancer cells to IM are provided.... Agent:

20130058996 - Liposome containing shrna molecule targeting a thymidylate synthase and use thereof: This method provides a method for delivering shRNA targeting TS in vivo. In addition, the following is provided: an antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface... Agent: Delta-fly Pharma, Inc.

20130058994 - Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis: The present invention provides compositions and methods for the treatment of multiple sclerosis. Among others, the invention provides compositions of immunodominant peptides of myelin basic protein encapsulated in mannosylated liposomes. In a specific embodiment, the compositions comprise mylein basic protein (MBP) peptides MBP(46-62), MBP(124-139), and MBP(147-170).... Agent:

20130058993 - Methods and compositions for enhancing wound healing using car peptides: Disclosed are compositions and methods useful for treating wounded, injured, and inflamed tissue. The compositions and methods are based on peptide sequences, such as CAR peptides and truncated CAR peptides, that are selectively targeted to wounded tissue and are internalized by a cell, penetrate tissue, or both. The disclosed peptides... Agent: Sanford-burnham Medical Research Institute

20130058997 - Vaccine composition containing synthetic adjuvant: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from... Agent: Infectious Disease Research Institute

20130058999 - Pharmaceutical compositions for oral administration of insulin peptides: The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such.... Agent: Novo Nordisk A/s

20130059000 - Oral delivery for hemoglobin based oxygen carriers: A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three exemplary composition configurations which include (1) hemoglobin-loaded nanoparticles solution, (2) enteric-coated hemoglobin capsules and (3) enteric-coated hemoglobin tablets. To facilitate the bioavailability and bio-compatibility... Agent:

20130059001 - Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of... Agent: Curemark LLC

20130059002 - Pharmaceutical compositions comprising a combination of metformin and sitagliptin: t

20130059005 - Bupropion hydrobromide polymorphs: Polymorphous and amorphous forms of bupropion hydrobromide are described.... Agent:

20130059004 - Oral drug delivery system: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a reactive composition located... Agent: Sun Pharma Advanced Research Company Ltd.

20130059003 - Sustained release donepezil formulations: Sustained release formulations comprising donepezil, or its pharmaceutically acceptable salts, and methods of preparing the sustained release formulations.... Agent: Dr. Reddy's Laboratories Ltd.

20130059006 - 3-dimensional cardiac fibroblast derived extracellular matrix: A bioscaffold made from an isolated cardiac fibroblast-derived 3-dimensional extracellular matrix (ECM) is disclosed. The bioscaffold can be used as an epicardial patch for the delivery of therapeutic cells into myocardial tissue. Methods of making the 3-dimensional extracellular matrix using cultured cardiac fibroblasts are also disclosed.... Agent: Wisconsin Alumni Research Foundation

20130059007 - Modified release formulations containing drug-ion exchange resin complexes: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing... Agent: Tris Pharma, Inc.

20130059008 - Drying methods for tuning microparticle properties: Described herein are drying methods for tuning one or more properties of a microparticle. In one aspect, the release profile of a microparticle comprising a bioactive agent therein can be affected by the disclosed drying methods.... Agent:

20130059009 - Compositions and methods for producing antigen-specific induced tolerogenic dendritic cells with synthetic nanocarriers: Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that are produced from combining itDCs with antigen in particulate form, as well as related compositions and methods.... Agent: Selecta Biosciences, Inc.

20130059010 - Alcohol-resistant oral pharmaceutical form: A sustained release oral pharmaceutical form suitable for single daily dose administration has a neutral microgranule coated with a mounting layer of active ingredient and pharmaceutically acceptable binder; and a coating layer of a hydrophobic coating polymer of a non-water soluble cellulose derivative, and at least 20% of inert load... Agent: Ethypharm

20130059011 - Bioactive bone graft substitute: The invention relates to biocompatible bone graft materials for repairing bone defects and the application of such bone graft materials.... Agent: Orthovita, Inc.

20130059013 - Injectable osteoinductive bone cements: e

20130059012 - Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines: The invention relates to methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in felines, comprising measuring particular inflammatory biomarkers. The invention further provides a method to treat or control inflammation comprising administering a diet comprising increased levels of one or... Agent: Hill's Pet Nutrition, Inc

20130059014 - Preservative for preserving wood and method for treating wood: wherein R represents an iropropyl group or an isopropoxy group as an active ingredient. The preservative for preserving wood has an excellent preservative effect on various wood-decay fungi at an extremely low dose, is economically efficient, and imposes a small burden on the environment. The present invention also relates to... Agent: Sds Biotech K. K.

20130059015 - Human cancer micro-rna expression profiles predictive of chemo-response: Disclosed are identified and successfully targeted microRNAs (miRNAs) associated with human cancer cell line response to a range of anti-cancer agents. The strategy of integrating in vitro miRNA expression and drug sensitivity data not only aid in the characterization of determinants of cytotoxic response, but also in the identification of... Agent: H. Lee Moffitt Cancer Center & Research Institute

20130059016 - Clay compositions: The present invention relates to liquid or semi-solid pharmaceutical compositions, more specifically to aqueous pharmaceutical suspension or semi-solid paste containing natural mineral clays as active ingredients. These compositions are particularly useful for the treatment of acute and chronic diarrhea.... Agent: Ipsen Pharma S.a.s

20130059017 - Topical nitric oxide systems and methods of use thereof: The present invention generally relates to compositions and methods for transdermal drug delivery. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction, treating wounds, or causing or promoting hair growth. For example, in one aspect, the present invention is generally directed to... Agent: Transdermal Biotechinology, Inc.

20130059018 - Phytocannabinoids in the treatment of cancer: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.... Agent: Gw Pharma Limited

20130059019 - Methods and compositions for treating inflammation of skin: The invention features methods of treating a subject suffering from a herpes simplex virus-induced inflammation by topically applying a composition including an effective amount of an antihistamine. The invention also features methods of treating inflammation by topically applying a base composition including essential extracts, either with or without one or... Agent: Exodus Life Sciences Limited Partnership

20130059020 - Cosmetic active ingredient preparation for increasing the long-term epidermal vitality of the skin: A cosmetic active ingredient preparation serves to increase the long-term epidermal vitality and reduce the wrinkle depth of a skin. The active ingredient preparation has at least 18% of a grape seed extract and at least 10% of a grape shoot and/or grape peel extract. Moreover, the active ingredient preparation... Agent:

20130059021 - Perfluoro(n-butylcyclohexane) compositions and uses thereof: A perfluoro(n-butylcyclohexane) composition is disclosed with numerous uses including topical and cosmetic applications, e.g., for application to the periocular skin or for the topical treatment of pruritus.... Agent: Oxygen Biotherapeutics, Inc.